Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTASXS1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS 22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS 23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS 24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS 25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 29	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

```
                organizations
 NEWS 32  JUN 30  STN on the Web enhanced with new STN AnaVist
                  Assistant and BLAST plug-in
 NEWS 33  JUN 30  STN AnaVist enhanced with database content from EPFULL

 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 18:31:20 ON 21 JUL 2008

=> file reg
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.21       0.21

FILE 'REGISTRY' ENTERED AT 18:31:30 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   20 JUL 2008  HIGHEST RN 1035004-20-6
DICTIONARY FILE UPDATES:  20 JUL 2008  HIGHEST RN 1035004-20-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10543109.str
```



chain nodes :
7 8 9 10 11 12 13 14 16 17 18 19 20 21 22 34
ring nodes :
1 2 3 4 5 6 15 23 24 25 26 27 28 29 30 31 32 33
chain bonds :
3-7 6-8 8-9 9-10 9-12 10-11 11-13 11-16 13-14 13-21 14-15 16-17 17-18
18-19 18-20 18-22 25-28 29-34
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-23 15-27 23-24 24-25 25-26 26-27 28-29
28-33 29-30 30-31 31-32 32-33
exact/norm bonds :
6-8 8-9 9-10 9-12 10-11 13-14 13-21 14-15 17-18 18-19 18-20 18-22 25-28
28-29 28-33 29-30 29-34 30-31 31-32 32-33
exact bonds :
3-7 11-13 11-16 16-17
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-23 15-27 23-24 24-25 25-26 26-27

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS

L1 STRUCTURE UPLOADED

=>
Uploading C:\Program Files\STNEXP\Queries\10543109a.str

chain nodes :
7 8 9 10 11 12 13 14 16 17 18 19 20 21 22 34 41 42 43 44 45 46
47 48 49 50 54
ring nodes :
1 2 3 4 5 6 15 23 24 25 26 27 28 29 30 31 32 33 35 36 37 38
39 40
chain bonds :
3-7 6-8 8-9 9-10 9-12 10-11 11-13 11-16 13-14 13-21 14-15 16-17 17-18
18-19 18-20 18-22 25-28 29-34 40-41 41-42 42-43 42-44 43-48 45-47 45-46
45-48 46-49 49-50 50-54
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-23 15-27 23-24 24-25 25-26 26-27 28-29
28-33 29-30 30-31 31-32 32-33 35-36 35-40 36-37 37-38 38-39 39-40
exact/norm bonds :
6-8 8-9 9-10 9-12 10-11 13-14 13-21 14-15 17-18 18-19 18-20 18-22 25-28
28-29 28-33 29-30 29-34 30-31 31-32 32-33 40-41 41-42 42-43 42-44 43-48
45-47 45-46 46-49 49-50 50-54
exact bonds :
3-7 11-13 11-16 16-17 45-48
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 15-23 15-27 23-24 24-25 25-26 26-27 35-36
35-40 36-37 37-38 38-39 39-40

G1:Cb,Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:Atom 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:Atom 24:Atom 25:Atom 26:Atom 27:Atom
28:Atom 29:Atom 30:Atom 31:Atom 32:Atom 33:Atom 34:CLASS 35:Atom 36:Atom
37:Atom 38:Atom 39:Atom 40:Atom 41:CLASS 42:CLASS 43:CLASS 44:CLASS
45:CLASS 46:CLASS 47:CLASS 48:CLASS 49:CLASS 50:CLASS 54:CLASS

L2 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR
*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> d l2
L2 HAS NO ANSWERS
L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss full
FULL SEARCH INITIATED 18:32:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 28 TO ITERATE

100.0% PROCESSED 28 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

L3 2 SEA SSS FUL L1

=> s l2 sss full
FULL SEARCH INITIATED 18:32:59 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L4 0 SEA SSS FUL L2

=>
Uploading C:\Program Files\STNEXP\Queries\10543109b.str





chain nodes :
7 8 9 10 11 12 13 14 15 16 20
ring nodes :
1 2 3 4 5 6
chain bonds :
6-7 7-8 8-9 8-10 9-14 11-13 11-12 11-14 12-15 15-16 16-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
6-7 7-8 8-9 8-10 9-14 11-13 11-12 12-15 15-16 16-20
exact bonds :
11-14
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

G1:Cb,Cy,Hy,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 20:CLASS

L5 STRUCTURE UPLOADED

=> s l5 sss full

FULL SEARCH INITIATED 18:33:55 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 30031 TO ITERATE

100.0% PROCESSED 30031 ITERATIONS 3513 ANSWERS
SEARCH TIME: 00.00.02

L6 3513 SEA SSS FUL L5

=> file capl
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 535.54 535.75

FILE 'CAPLUS' ENTERED AT 18:34:00 ON 21 JUL 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 21 Jul 2008 VOL 149 ISS 4
FILE LAST UPDATED: 20 Jul 2008 (20080720/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> s l6
L7 52 L6

=> s l3
L8 3 L3

=> d l8 1-3 ibib

L8 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1061760 CAPLUS
DOCUMENT NUMBER: 146:54689
TITLE: Design and evaluation of a novel class-directed 2D fingerprint to search for structurally diverse active compounds
AUTHOR(S): Eckert, Hanna; Bajorath, Juergen
CORPORATE SOURCE: Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universitaet, Bonn, D-53113, Germany
SOURCE: Journal of Chemical Information and Modeling (2006), 46(6), 2515-2526
CODEN: JCISD8; ISSN: 1549-9596
PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal
LANGUAGE: English
REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:605492 CAPLUS
DOCUMENT NUMBER: 141:157122
TITLE: Preparation of ureidoazinylalkanamides as inhibitors of blood coagulation Factor VIIa and Xa.
INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes; Van Amsterdam, Christoph
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10302500	A1	20040729	DE 2003-10302500	20030123
AU 2004205354	A1	20040805	AU 2004-205354	20040108
CA 2514100	A1	20040805	CA 2004-2514100	20040108
WO 2004065369	A1	20040805	WO 2004-EP61	20040108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1585730	A1	20051019	EP 2004-700684	20040108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006844	A	20051213	BR 2004-6844	20040108
CN 1741996	A	20060301	CN 2004-80002520	20040108
JP 2006516566	T	20060706	JP 2006-500530	20040108
MX 2005PA07715	A	20050930	MX 2005-PA7715	20050720
US 20060074072	A1	20060406	US 2005-543109	20050722
ZA 2005006730	A	20060531	ZA 2005-6730	20050822
PRIORITY APPLN. INFO.:			DE 2003-10302500 A	20030123
			WO 2004-EP61 A	20040108

OTHER SOURCE(S): MARPAT 141:157122

L8 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:308415 CAPLUS
DOCUMENT NUMBER: 140:321240
TITLE: Preparation of lactam-containing diaminoalkanes, β-amino acids, α-amino acids and derivatives thereof as factor Xa inhibitors
INVENTOR(S): Qiao, Jennifer X.; Han, Wei
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031145	A2	20040415	WO 2003-US31079	20031001

```
     WO 2004031145         A3    20040701
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
             GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
             LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
             OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     US 20040077635        A1    20040422    US 2003-677063         20031001
     AU 2003279735         A1    20040423    AU 2003-279735         20031001
     EP 1558606            A2    20050803    EP 2003-773077         20031001
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     US 20070129361        A1    20070607    US 2007-622484         20070112
PRIORITY APPLN. INFO.:                       US 2002-415366P     P  20021002
                                             US 2002-417208P     P  20021009
                                             US 2003-677063      A1 20031001
                                             WO 2003-US31079     W  20031001
OTHER SOURCE(S):         MARPAT 140:321240


=> s l7 or l8
L9          52 L7 OR L8

=> d 1-52 ibib hitstr

L9   ANSWER 1 OF 52  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2007:1449482  CAPLUS
DOCUMENT NUMBER:         148:55072
TITLE:                   Preparation of 6-[(sulfamoyl)amino]- and
                         6-[(sulfamoyl)oxy]hexanoic acid and derivatives as
                         histone deacetylase (HDAC) inhibitors
INVENTOR(S):             Smil, David; Leit, Silvana; Ajamian, Alain; Allan,
                         Martin; Chantigny, Yves Andre; Deziel, Robert;
                         Therrien, Eric; Wahhab, Amal; Manku, Sukhdev
PATENT ASSIGNEE(S):      Methylgene Inc., Can.
SOURCE:                  U.S. Pat. Appl. Publ., 245pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     US 20070293530        A1    20071220    US 2007-762874          20070614
     WO 2007143822         A1    20071221    WO 2007-CA1024          20070614
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,
             CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,
             GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
             KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG,
             MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,
             RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
             TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
             IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
             GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM
```

PRIORITY APPLN. INFO.: US 2006-804719P P 20060614
OTHER SOURCE(S): MARPAT 148:55072
IT 960130-05-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 6-[(sulfamoyl)amino]- and 6-[(sulfamoyl)oxy]hexanoic acid and derivs. as histone deacetylase (HDAC) inhibitors)
RN 960130-05-6 CAPLUS
CN 3-Thia-2,4,10-triazaundecanoic acid, 11-oxo-11-(phenylamino)-9-[[(4-phenyl-2-thiazolyl)amino]carbonyl]-, 1,1-dimethylethyl ester, 3,3-dioxide, (9S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 960130-01-2P 960131-17-3P 960131-18-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 6-[(sulfamoyl)amino]- and 6-[(sulfamoyl)oxy]hexanoic acid and derivs. as histone deacetylase (HDAC) inhibitors)
RN 960130-01-2 CAPLUS
CN Hexanamide, 6-[(aminosulfonyl)amino]-2-[[(phenylamino)carbonyl]amino]-N-(4-phenyl-2-thiazolyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 960131-17-3 CAPLUS
CN Hexanamide, 6-[(aminosulfonyl)amino]-2-[[[(4-methoxyphenyl)amino]carbonyl]amino]-N-(4-phenyl-2-thiazolyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 960131-18-4 CAPLUS
CN Hexanamide, 6-[(aminosulfonyl)amino]-2-[[[(4-fluorophenyl)amino]carbonyl]amino]-N-(4-phenyl-2-thiazolyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 2 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:412520 CAPLUS
DOCUMENT NUMBER: 147:1112
TITLE: Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer
AUTHOR(S): Zhang, Qing; Bhola, Neil E.; Lui, Vivian Wai Yan; Siwak, Doris R.; Thomas, Sufi M.; Gubish, Christopher T.; Siegfried, Jill M.; Mills, Gordon B.; Shin, Dong; Grandis, Jennifer Rubin
CORPORATE SOURCE: Departments of Otolaryngology and Pharmacology, University of Pittsburgh School of Medicine and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
SOURCE: Molecular Cancer Therapeutics (2007), 6(4), 1414-1424
CODEN: MCTOCF; ISSN: 1535-7163
PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204067-01-6, PD176252
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer)
RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 3 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:396443 CAPLUS
DOCUMENT NUMBER: 147:31355
TITLE: Solid-phase synthesis of a thymidinyl dipeptide urea library
AUTHOR(S): Sun, Dianqing; Lee, Richard E.
CORPORATE SOURCE: Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA
SOURCE: Journal of Combinatorial Chemistry (2007), 9(3), 370-385
CODEN: JCCHFF; ISSN: 1520-4766
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:31355
IT 938048-04-5P 938048-07-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(solid-phase preparation of thymidinyl dipeptide urea library using azidodeoxythymidine as starting material via coupling with Fmoc-amino acids and alkyl- or arylisocyanate)
RN 938048-04-5 CAPLUS
CN Thymidine, 5'-deoxy-5'-[[(2S)-1-oxo-2-[[(phenylamino)carbonyl]amino]propyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 938048-07-8 CAPLUS
CN Thymidine, 5'-deoxy-5'-[[(2S)-1-oxo-3-phenyl-2-[[(phenylamino)carbonyl]amino]propyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:16780 CAPLUS
DOCUMENT NUMBER: 146:122298
TITLE: Preparation of amino acid amides as non-nucleoside anti-hepacivirus agents
INVENTOR(S): Boyd, Vincent A.; Cameron, Dale R.; Jia, Qi; Sgarbi, Paulo W. M.; Wacowich-Sgarbi, Shirley A.
PATENT ASSIGNEE(S): Migenix Inc., Can.
SOURCE: PCT Int. Appl., 303pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007002639	A2	20070104	WO 2006-US24919	20060626
WO 2007002639	A3	20070712		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,

SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

CA 2613354	A1	20070104	CA 2006-2613354		20060626
US 20070021434	A1	20070125	US 2006-426580		20060626
EP 1910279	A2	20080416	EP 2006-774070		20060626

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: US 2005-693569P P 20050624
WO 2006-US24919 W 20060626

OTHER SOURCE(S): MARPAT 146:122298

IT 918433-55-3P, (S)-6-Amino-2-[3-(4-benzyloxyphenyl)ureido]hexanoic acid N-(4-cyclohexylphenyl)amide 918433-57-5P, (S)-6-Amino-2-[3-(biphenyl-4-yl)ureido]hexanoic acid N-(4-cyclohexylphenyl)amide 918433-59-7P, (S)-7-Amino-2-[3-(4-benzyloxyphenyl)ureido]heptanoic acid N-(4-cyclohexylphenyl)amide 918433-81-5P, (R)-6-Amino-2-[3-(9H-fluoren-2-yl)ureido]hexanoic acid N-(4-cyclohexylphenyl)amide 918433-91-7P, (R)-6-Amino-2-[3-(biphenyl-4-yl)ureido]hexanoic acid N-(4-cyclohexylphenyl)amide 918434-24-9P, (R)-6-Amino-2-[3-(4-benzyloxyphenyl)ureido]hexanoic acid N-(4-cyclohexylphenyl)amide 918434-62-5P, (R)-5-Amino-2-[3-(biphenyl-4-yl)ureido]pentanoic acid N-(4-cyclohexylphenyl)amide 918434-63-6P, (R)-5-Amino-2-[3-(4-benzyloxyphenyl)ureido]pentanoic acid N-(4-cyclohexylphenyl)amide 918434-64-7P, (R)-5-Amino-2-[3-(9H-fluoren-2-yl)ureido]pentanoic acid N-(4-cyclohexylphenyl)amide 918434-88-5P, (S)-6-Amino-2-[3-(9H-fluoren-2-yl)ureido]hexanoic acid N-(4-cyclohexylphenyl)amide 918435-78-6P, (S)-6-Amino-2-[3-(4-benzyloxyphenyl)ureido]hexanoic acid N-(5-methyl-2-phenyl-2H-pyrazol-3-yl)amide 918435-79-7P, (S)-6-Amino-2-[3-(4-benzyloxyphenyl)ureido]hexanoic acid N-[4-(imidazol-1-yl)phenyl]amide 918435-85-5P, 2-[1-(4-Aminobutyl)-3-(4-benzyloxyphenyl)ureido]-N-(4-cyclohexylphenyl)acetamide 918435-86-6P, 2-[1-(4-Aminobutyl)-3-(4-styrylphenyl)ureido]-N-(4-cyclohexylphenyl)acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid amides as non-nucleoside anti-hepacivirus agents)

RN 918433-55-3 CAPLUS
CN Hexanamide, 6-amino-N-(4-cyclohexylphenyl)-2-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918433-57-5 CAPLUS
CN Hexanamide, 6-amino-2-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino]-N-(4-cyclohexylphenyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918433-59-7 CAPLUS
CN Heptanamide, 7-amino-N-(4-cyclohexylphenyl)-2-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918433-81-5 CAPLUS

CN Hexanamide, 6-amino-N-(4-cyclohexylphenyl)-2-[[(9H-fluoren-2-ylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918433-91-7 CAPLUS
CN Hexanamide, 6-amino-2-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino]-N-(4-cyclohexylphenyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918434-24-9 CAPLUS
CN Hexanamide, 6-amino-N-(4-cyclohexylphenyl)-2-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918434-62-5 CAPLUS
CN Pentanamide, 5-amino-2-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino]-N-(4-cyclohexylphenyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918434-63-6 CAPLUS
CN Pentanamide, 5-amino-N-(4-cyclohexylphenyl)-2-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918434-64-7 CAPLUS

CN Pentanamide, 5-amino-N-(4-cyclohexylphenyl)-2-[[(9H-fluoren-2-ylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918434-88-5 CAPLUS
CN Hexanamide, 6-amino-N-(4-cyclohexylphenyl)-2-[[(9H-fluoren-2-ylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918435-78-6 CAPLUS
CN Hexanamide, 6-amino-N-(3-methyl-1-phenyl-1H-pyrazol-5-yl)-2-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918435-79-7 CAPLUS
CN Hexanamide, 6-amino-N-[4-(1H-imidazol-1-yl)phenyl]-2-[[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 918435-85-5 CAPLUS
CN Acetamide, 2-[(4-aminobutyl)[[[4-(phenylmethoxy)phenyl]amino]carbonyl]amino]-N-(4-cyclohexylphenyl)- (CA INDEX NAME)



RN 918435-86-6 CAPLUS
CN Acetamide, 2-[(4-aminobutyl)[[[4-(2-phenylethenyl)phenyl]amino]carbonyl]amino]-N-(4-cyclohexylphenyl)- (CA INDEX NAME)



L9 ANSWER 5 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1147636 CAPLUS
DOCUMENT NUMBER: 145:465721
TITLE: Therapeutic agents for irritable bowel syndrome containing bombesin 2 receptor antagonists
INVENTOR(S): Yamano, Mayumi
PATENT ASSIGNEE(S): Astellas Pharma Inc., Japan
SOURCE: PCT Int. Appl., 39pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006115135	A1	20061102	WO 2006-JP308173	20060419

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1872795	A1	20080102	EP 2006-732080	20060419

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR

PRIORITY APPLN. INFO.: JP 2005-123682 A 20050421
WO 2006-JP308173 W 20060419

IT 204067-01-6, PD 176252
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic agents for irritable bowel syndrome containing bombesin 2 receptor antagonists)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1133797 CAPLUS
DOCUMENT NUMBER: 145:410541
TITLE: Bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity
AUTHOR(S): Merali, Zul; Bedard, Tania; Andrews, Nick; Davis, Ben;

AUTHOR(S): McKnight, Alexander T.; Gonzalez, M. Isabel; Pritchard, Martyn; Kent, Pam; Anisman, Hymie
CORPORATE SOURCE: Institute of Mental Health Research and Departments of Psychiatry and Cellular and Molecular Medicine, University of Ottawa, Ottawa, ON, K1N 6N5, Can.
SOURCE: Journal of Neuroscience (2006), 26(41), 10387-10396
CODEN: JNRSDS; ISSN: 0270-6474
PUBLISHER: Society for Neuroscience
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204067-01-6, PD 176252
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin receptors as a novel anti-anxiety therapeutic target: BB1 receptor actions on anxiety through alterations of serotonin activity)
RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1061760 CAPLUS
DOCUMENT NUMBER: 146:54689
TITLE: Design and evaluation of a novel class-directed 2D fingerprint to search for structurally diverse active compounds
AUTHOR(S): Eckert, Hanna; Bajorath, Juergen
CORPORATE SOURCE: Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universitaet, Bonn, D-53113, Germany
SOURCE: Journal of Chemical Information and Modeling (2006), 46(6), 2515-2526
CODEN: JCISD8; ISSN: 1549-9596
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 678178-11-5

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(design and evaluation of class-directed two-dimensional mol. fingerprint to search for structurally diverse active compds.)

RN 678178-11-5 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 8 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:979736 CAPLUS

DOCUMENT NUMBER: 145:357107

TITLE: Preparation of ramoplanin derivatives possessing antibacterial activity

INVENTOR(S): Raju, Bore G.; Ciabatti, Romeo; Maffioli, Sonia Ilaria; Singh, Upinder; Romano, Gabriella; Michelucci, Elena; Tiseni, Paolo Simone; Candiani, Gianpaolo; Kim, Bum; O'Dowd, Hardwin

PATENT ASSIGNEE(S): Vicuron Pharmaceuticals Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 119pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211603	A1	20060921	US 2005-198763	20050804
WO 2007001335	A2	20070104	WO 2005-US28704	20050811

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 2004-602780P	P	20040818
	US 2005-198763	A	20050804

OTHER SOURCE(S): MARPAT 145:357107

IT 910320-50-2P 910320-51-3P 910320-52-4P
910320-53-5P 910320-54-6P 910320-55-7P

910320-56-8P 910320-58-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ramoplanin derivs. having antibacterial activity)

RN 910320-50-2 CAPLUS

CN Ramoplanin A 1, 1-[N2-[(phenylamino)carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 3-A







PAGE 4-A





RN 910320-51-3 CAPLUS
CN Ramoplanin A 1, 1-[N2-[[[2-(trifluoromethyl)phenyl]amino]carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



RN 910320-52-4 CAPLUS
CN Ramoplanin A 1, 1-[N2-[[[3-(trifluoromethyl)phenyl]amino]carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



RN 910320-53-5 CAPLUS
CN Ramoplanin A 1, 1-[N2-[[[4-(trifluoromethyl)phenyl]amino]carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



RN 910320-54-6 CAPLUS
CN Ramoplanin A 1, 1-[N2-[[(2-methoxyphenyl)amino]carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



RN 910320-55-7 CAPLUS
CN Ramoplanin A 1, 1-[N2-[[(2,6-dimethylphenyl)amino]carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



RN 910320-56-8 CAPLUS
CN Ramoplanin A 1, 1-[N2-[(1-naphthalenylamino)carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



RN 910320-58-0 CAPLUS
CN Ramoplanin A 1, 1-[N2-[[(2-methylphenyl)amino]carbonyl]-L-asparagine]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



PAGE 3-A





PAGE 4-A







PAGE 5-A



L9 ANSWER 9 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:558817 CAPLUS
DOCUMENT NUMBER: 145:63142
TITLE: Preparation of amino acid urea derivatives as factor Xa inhibitors
INVENTOR(S): Song, Yonghong; Zhu, Bing-Yan; Wang, Shumei; Bhakta, Chhaya; Scarborough, Robert M.
PATENT ASSIGNEE(S): Portola Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006063113	A2	20060615	WO 2005-US44388	20051207
WO 2006063113	A3	20070510		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
US 20060160821 A1 20060720 US 2005-298317 20051207
PRIORITY APPLN. INFO.: US 2004-634201P P 20041207
OTHER SOURCE(S): MARPAT 145:63142
IT 891788-33-3P 891788-46-8P 891788-79-7P
891788-85-5P 891788-89-9P 891788-90-2P
891788-91-3P 891788-92-4P 891789-07-4P
891789-14-3P 891789-60-9P 891789-62-1P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of amino acid urea derivs. as factor Xa inhibitors)

RN 891788-33-3 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-3,3-dimethyl- (CA INDEX NAME)



RN 891788-46-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-79-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891788-85-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-2-fluoro- (CA INDEX NAME)



RN 891788-89-9 CAPLUS
CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, phenylmethyl ester, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891788-90-2 CAPLUS
CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, (3S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891788-91-3 CAPLUS
CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, phenylmethyl ester, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891788-92-4 CAPLUS
CN Butanoic acid, 3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-4-oxo-, (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891789-07-4 CAPLUS
CN Benzeneacetamide, 2-bromo-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-14-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-methyl- (CA INDEX NAME)



RN 891789-60-9 CAPLUS
CN 4-Hexynamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-62-1 CAPLUS
CN 4-Pentenamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



IT 891788-31-1P 891788-32-2P 891788-34-4P
891788-35-5P 891788-36-6P 891788-37-7P
891788-38-8P 891788-39-9P 891788-40-2P
891788-41-3P 891788-42-4P 891788-43-5P
891788-44-6P 891788-47-9P 891788-48-0P
891788-60-6P 891788-61-7P 891788-62-8P
891788-70-8P 891788-80-0P 891788-81-1P
891788-82-2P 891788-86-6P 891788-87-7P
891788-88-8P 891788-93-5P 891788-94-6P
891788-95-7P 891788-96-8P 891788-97-9P
891788-98-0P 891788-99-1P 891789-00-7P
891789-01-8P 891789-03-0P 891789-04-1P
891789-05-2P 891789-06-3P 891789-08-5P
891789-09-6P 891789-15-4P 891789-18-7P
891789-19-8P 891789-22-3P 891789-23-4P
891789-25-6P 891789-29-0P 891789-32-5P
891789-35-8P 891789-36-9P 891789-37-0P
891789-38-1P 891789-41-6P 891789-44-9P
891789-45-0P 891789-49-4P 891789-50-7P
891789-51-8P 891789-52-9P 891789-53-0P
891789-54-1P 891789-55-2P 891789-56-3P

891789-59-6P 891789-61-0P 891789-63-2P
891789-67-6P 891789-68-7P 891789-70-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid urea derivs. as factor Xa inhibitors)

RN 891788-31-1 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-32-2 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-3-methyl- (CA INDEX NAME)



RN 891788-34-4 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-4,4-dimethyl- (CA INDEX NAME)



RN 891788-35-5 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-36-6 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-37-7 CAPLUS
CN 1H-Imidazole-5-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-38-8 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-1-methyl- (CA INDEX NAME)



RN 891788-39-9 CAPLUS
CN 3-Pyridineacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-

(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-40-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-4-fluoro- (CA INDEX NAME)



RN 891788-41-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-fluoro- (CA INDEX NAME)



RN 891788-42-4 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-43-5 CAPLUS
CN 3-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-44-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-α-phenyl- (CA INDEX NAME)



RN 891788-47-9 CAPLUS
CN 2-Thiopheneacetamide, N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-α-[[[(4-fluorophenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 891788-48-0 CAPLUS
CN 2-Thiopheneacetamide, N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-α-[[[(4-ethynylphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 891788-60-6 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-bromophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891788-61-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891788-62-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891788-70-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-bromophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-fluoro- (CA INDEX NAME)



RN 891788-80-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(1-oxido-4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891788-81-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891788-82-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-bromophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891788-86-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-fluoro- (CA INDEX NAME)



RN 891788-87-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-bromophenyl)amino]carbonyl]amino]-N-[2'-[(dimethylamino)methyl]-3-fluoro[1,1'-biphenyl]-4-yl]-2-fluoro- (CA INDEX NAME)



RN 891788-88-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-fluoro- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 891788-93-5 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4,N4-dimethyl- (CA INDEX NAME)



RN 891788-94-6 CAPLUS
CN 1-Piperidinebutanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-γ-oxo- (CA INDEX NAME)



RN 891788-95-7 CAPLUS
CN 4-Morpholinebutanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-γ-oxo- (CA INDEX NAME)



RN 891788-96-8 CAPLUS
CN 1-Pyrrolidinebutanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-γ-oxo- (CA

INDEX NAME)



RN 891788-97-9 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-[3-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-[[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]amino]-1,4-dioxobutyl]-, ethyl ester (CA INDEX NAME)



RN 891788-98-0 CAPLUS
CN 1H-Azepine-1-butanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]hexahydro-γ-oxo- (CA INDEX NAME)



RN 891788-99-1 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4-(phenylmethyl)- (CA INDEX NAME)



RN 891789-00-7 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4-methyl- (CA INDEX NAME)



RN 891789-01-8 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-03-0 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-N4-phenyl- (CA INDEX NAME)



RN 891789-04-1 CAPLUS
CN Benzeneacetamide, 3-chloro-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-05-2 CAPLUS
CN Benzeneacetamide, 2-chloro-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-06-3 CAPLUS

CN 1,3-Benzodioxole-5-acetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-08-5 CAPLUS
CN Benzeneacetamide, 2-bromo-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-4-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-09-6 CAPLUS
CN Benzeneacetamide, 2-bromo-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-15-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 891789-18-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-19-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[(dimethylamino)methyl][1,1'-biphenyl]-4-yl]-2-methyl- (CA INDEX NAME)



RN 891789-22-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]-2-methyl- (CA INDEX NAME)



RN 891789-23-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 891789-25-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 891789-29-0 CAPLUS
CN Benzeneacetamide, 2-chloro-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-32-5 CAPLUS
CN Benzeneacetamide, 2-chloro-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]- (CA INDEX NAME)



RN 891789-35-8 CAPLUS
CN Benzeneacetamide, 2-chloro-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 891789-36-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-methoxy- (CA INDEX NAME)



RN 891789-37-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-

methoxy-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-38-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methoxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 891789-41-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(hexahydro-4-methyl-1H-1,4-diazepin-1-yl)phenyl]-2-methoxy- (CA INDEX NAME)



RN 891789-44-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-iodo- (CA INDEX NAME)



RN 891789-45-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-iodo-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-49-4 CAPLUS
CN Benzeneacetamide, 4-bromo-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-50-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 891789-51-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]-2-(trifluoromethoxy)- (CA INDEX NAME)



RN 891789-52-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-[(trifluoromethyl)thio]- (CA INDEX NAME)



RN 891789-53-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]-2-[(trifluoromethyl)thio]- (CA INDEX NAME)



RN 891789-54-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]-2-phenoxy- (CA INDEX NAME)



RN 891789-55-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]-2-phenoxy- (CA INDEX NAME)



RN 891789-56-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-(methylthio)-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-59-6 CAPLUS
CN 4-Pentynamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4,5-dihydro-1-methyl-1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)



RN 891789-61-0 CAPLUS
CN 4-Hexynamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-63-2 CAPLUS
CN 4-Pentenamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-oxido-2-pyridinyl)phenyl]- (CA INDEX NAME)



RN 891789-67-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891789-68-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 891789-70-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 10 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:505914 CAPLUS
DOCUMENT NUMBER: 145:95784
TITLE: The discovery of glycine and related amino acid-based factor Xa inhibitors
AUTHOR(S): Kohrt, Jeffrey T.; Filipski, Kevin J.; Cody, Wayne L.; Bigge, Christopher F.; La, Frances; Welch, Kathleen; Dahring, Tawny; Bryant, John W.; Leonard, Daniele; Bolton, Gary; Narasimhan, Lakshmi; Zhang, Erli; Peterson, J. Thomas; Haarer, Staci; Sahasrabudhe, Vaishali; Janiczek, Nancy; Desiraju, Shrilakshmi; Hena, Mostofa; Fiakpui, Charles; Saraswat, Neerja; Sharma, Raman; Sun, Shaoyi; Maiti, Samarendra N.; Leadley, Robert; Edmunds, Jeremy J.
CORPORATE SOURCE: Michigan Labs, Pfizer Global Research and Development, Ann Arbor, MI, 48105, USA
SOURCE: Bioorganic & Medicinal Chemistry (2006), 14(13), 4379-4392
CODEN: BMECEP; ISSN: 0968-0896
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 145:95784
IT 675833-75-7P 675833-79-1P 675833-89-3P
675833-96-2P 675834-22-7P 675834-25-0P
675834-26-1P 675834-27-2P 675834-28-3P
675834-29-4P 896420-91-0P 896420-92-1P
896420-93-2P 896420-94-3P 896420-95-4P
896420-96-5P 896420-97-6P 896420-98-7P
896420-99-8P 896421-00-4P 896421-01-5P
896421-02-6P 896421-03-7P 896421-04-8P
896421-05-9P 896421-06-0P 896421-07-1P
896421-08-2P 896421-09-3P 896421-10-6P
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(glycine and related amino acid-based factor Xa inhibitors)
RN 675833-75-7 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-methyl- (CA INDEX NAME)



RN 675833-79-1 CAPLUS
CN Propanamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl- (CA INDEX NAME)



RN 675833-89-3 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]methylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675833-96-2 CAPLUS
CN Propanamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-hydroxy-2-(hydroxymethyl)- (CA INDEX NAME)



RN 675834-22-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclopropylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-25-0 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-26-1 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methylpropyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-27-2 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][2-(dimethylamino)ethyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-28-3 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](phenylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-29-4 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(4-methoxyphenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-91-0 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-92-1 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]ethylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-93-2 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]propylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-94-3 CAPLUS
CN Acetamide, 2-[butyl[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-95-4 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2,2-dimethylpropyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-96-5 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]cyclopropylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-97-6 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclobutylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-98-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclopentylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896420-99-8 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclohexylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-00-4 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(tetrahydro-3-furanyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-01-5 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-furanylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-02-6 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-thienylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-03-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-oxazolylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-04-8 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](3-thienylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-05-9 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(3-methoxyphenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-06-0 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(3-fluorophenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-07-1 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(3-methylphenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-08-2 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(2-methoxyphenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-09-3 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(2-chlorophenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 896421-10-6 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(4-chlorophenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-

4-yl]- (CA INDEX NAME)



IT 675834-30-7 896420-90-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(glycine and related amino acid-based factor Xa inhibitors)
RN 675834-30-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 896420-90-9 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclopropylmethyl)amino]-N-[2-fluoro-4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 11 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:472618 CAPLUS
DOCUMENT NUMBER: 145:95979
TITLE: Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation
AUTHOR(S): Moody, Terry W.; Nakagawa, Tomoo; Kang, Yang; Jakowlew, Sonia; Chan, Daniel; Jensen, Robert T.
CORPORATE SOURCE: Department of Health and Human Services, Office of the Director, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA
SOURCE: Journal of Molecular Neuroscience (2006), 28(3), 231-238
CODEN: JMNEES; ISSN: 0895-8696
PUBLISHER: Humana Press Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204067-01-6, PD176252
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(synergism of bombesin/gastrin-releasing peptide receptor antagonists with histone deacetylase inhibitors in lung cancer)
RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 12 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:149498 CAPLUS
DOCUMENT NUMBER: 144:213019
TITLE: Preparation of amino hydroxamic acid urea derivatives as histone deacetylase inhibitors
INVENTOR(S): Belvedere, Sandro; Hamblett, Christopher Laurence; Miller, Thomas A.; Witter, David J.; Yan, Jiaming
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Aton Pharma, Inc.
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006017216	A1	20060216	WO 2005-US24514		20050708
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2005271843	A1	20060216	AU 2005-271843		20050708
CA 2573413	A1	20060216	CA 2005-2573413		20050708
EP 1773761	A1	20070418	EP 2005-769269		20050708
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 1997627	A	20070711	CN 2005-80023455		20050708
JP 2008505971	T	20080228	JP 2007-521532		20050708
US 20080033015	A1	20080207	US 2006-629447		20061213
IN 2007DN01005	A	20070427	IN 2007-DN1005		20070207
PRIORITY APPLN. INFO.:			US 2004-587186P	P	20040712
			WO 2005-US24514	W	20050708

OTHER SOURCE(S): CASREACT 144:213019; MARPAT 144:213019
IT 876054-83-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino hydroxamic acid urea derivs. as histone deacetylase inhibitors)
RN 876054-83-0 CAPLUS
CN Octanediamide, N8-hydroxy-2-[[(phenylamino)carbonyl]amino]-N1-(4-phenyl-2-thiazolyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 13 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:738402 CAPLUS
DOCUMENT NUMBER: 141:243828
TITLE: Synthesis of amino acid ethylene derivatives for use

as coagulation factor Xa inhibitors for treatment of disease

INVENTOR(S): Mederski, Werner; Tsaklakidis, Christos; Dorsch, Dieter; Cezanne, Bertram; Gleitz, Johannes; Van Amsterdam, Christoph

PATENT ASSIGNEE(S): Merck Patent GmbH, Germany

SOURCE: Ger. Offen., 19 pp.
CODEN: GWXXBX

DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10308907	A1	20040909	DE 2003-10308907	20030228
AU 2004215708	A1	20040910	AU 2004-215708	20040130
CA 2517391	A1	20040910	CA 2004-2517391	20040130
WO 2004076429	A1	20040910	WO 2004-EP817	20040130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1597244	A1	20051123	EP 2004-706669	20040130
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007865	A	20060301	BR 2004-7865	20040130
CN 1753882	A	20060329	CN 2004-80005443	20040130
JP 2006519188	T	20060824	JP 2006-501655	20040130
MX 2005PA09002	A	20051018	MX 2005-PA9002	20050824
US 20060084648	A1	20060420	US 2005-547130	20050826

PRIORITY APPLN. INFO.: DE 2003-10308907 A 20030228
WO 2004-EP817 W 20040130

OTHER SOURCE(S): MARPAT 141:243828

IT 749250-59-7P
RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of amino acid ethylene derivs. for use as coagulation factor Xa inhibitors for treatment of disease)

RN 749250-59-7 CAPLUS

CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 749250-60-0 749250-61-1 749250-62-2
749250-64-4
RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid ethylene derivs. for use as coagulation factor Xa inhibitors for treatment of disease)
RN 749250-60-0 CAPLUS
CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-4-methyl-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 749250-61-1 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 749250-62-2 CAPLUS
CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-methoxy-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 749250-64-4 CAPLUS
CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-hydroxy-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 749250-66-6 749250-67-7 749250-68-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of amino acid ethylene derivs. for use as coagulation factor Xa inhibitors for treatment of disease)

RN 749250-66-6 CAPLUS

CN Pentanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 749250-67-7 CAPLUS

CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-methoxy-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 749250-68-8 CAPLUS

CN Propanamide, 2-[[[(4-ethynylphenyl)amino]carbonyl]amino]-3-hydroxy-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 14 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:605492 CAPLUS
DOCUMENT NUMBER: 141:157122
TITLE: Preparation of ureidoazinylalkanamides as inhibitors of blood coagulation Factor VIIa and Xa.
INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Mederski, Werner; Tsaklakidis, Christos; Gleitz, Johannes; Van Amsterdam, Christoph
PATENT ASSIGNEE(S): Merck Patent GmbH, Germany
SOURCE: Ger. Offen., 25 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10302500	A1	20040729	DE 2003-10302500	20030123
AU 2004205354	A1	20040805	AU 2004-205354	20040108
CA 2514100	A1	20040805	CA 2004-2514100	20040108
WO 2004065369	A1	20040805	WO 2004-EP61	20040108
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
EP 1585730	A1	20051019	EP 2004-700684	20040108
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004006844	A	20051213	BR 2004-6844	20040108
CN 1741996	A	20060301	CN 2004-80002520	20040108
JP 2006516566	T	20060706	JP 2006-500530	20040108
MX 2005PA07715	A	20050930	MX 2005-PA7715	20050720
US 20060074072	A1	20060406	US 2005-543109	20050722
ZA 2005006730	A	20060531	ZA 2005-6730	20050822

PRIORITY APPLN. INFO.: DE 2003-10302500 A 20030123
WO 2004-EP61 A 20040108

OTHER SOURCE(S): MARPAT 141:157122
IT 678178-11-5P 728945-08-2P 728945-09-3P
728945-10-6P 728945-11-7P 728945-13-9P
728945-14-0P 728945-16-2P 728945-17-3P
728945-18-4P 728945-19-5P 728945-20-8P
728945-21-9P 728945-22-0P 728945-23-1P
728945-24-2P 728945-25-3P 728945-26-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ureidoazinylalkanamides as inhibitors of Factor VIIa and Xa)

RN 678178-11-5 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 728945-08-2 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]- (CA INDEX NAME)



RN 728945-09-3 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 728945-10-6 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 728945-11-7 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 728945-13-9 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 728945-14-0 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(methylsulfonyl)-

N-[4-(3-oxo-4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 728945-16-2 CAPLUS
CN 1-Propanesulfonic acid, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]- (CA INDEX NAME)



RN 728945-17-3 CAPLUS
CN 1-Propanesulfonic acid, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(2-oxo-1(2H)-pyridinyl)phenyl]amino]- (CA INDEX NAME)



RN 728945-18-4 CAPLUS
CN Phosphonic acid, [(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 728945-19-5 CAPLUS
CN Phosphonic acid, [2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(2-oxo-1-piperidinyl)phenyl]amino]propyl]-, dimethyl ester (9CI) (CA INDEX NAME)



RN 728945-20-8 CAPLUS
CN Phosphonic acid, [2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-oxo-3-[[4-(3-oxo-4-morpholinyl)phenyl]amino]propyl]- (9CI) (CA INDEX NAME)



RN 728945-21-9 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(S-methylsulfonimidoyl)-N-[4-(3-oxo-4-morpholinyl)phenyl]- (9CI) (CA INDEX NAME)



RN 728945-22-0 CAPLUS
CN Propanamide, 3-(aminosulfonyl)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 728945-23-1 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-[(methylsulfonyl)amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 728945-24-2 CAPLUS
CN Propanamide, 3-[(aminosulfonyl)oxy]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 728945-25-3 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-methyl-4-(3-oxo-4-morpholinyl)phenyl]-3-(methylsulfonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 728945-26-4 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(dihydro-2-oxo-2H-1,3-oxazin-3(4H)-yl)phenyl]-3-(methylsulfonyl)-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



IT 728945-29-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of ureidoazinylalkanamides as inhibitors of Factor VIIa and Xa)

RN 728945-29-7 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-(methylthio)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 15 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:523308 CAPLUS
DOCUMENT NUMBER: 141:225134
TITLE: Parallel synthesis and structure-activity relationships of a series of highly potent, selective, and neutral factor Xa inhibitors
AUTHOR(S): Bauer, Shawn M.; Goldman, Erick A.; Huang, Wenrong; Su, Ting; Wang, Lingyan; Woolfrey, John; Wu, Yanhong; Zuckett, Jingmei F.; Arfsten, Ann; Huang, Brian; Kothule, Jaya; Lin, Joyce; May, Bridget; Sinha, Uma; Wong, Paul W.; Hutchaleelaha, Athiwat; Scarborough, Robert M.; Zhu, Bing-Yan
CORPORATE SOURCE: Department of Medicinal Chemistry, Millennium Pharmaceuticals, Inc., San Francisco, CA, 94080, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(15), 4045-4050
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:225134
IT 745021-03-8
RL: PAC (Pharmacological activity); BIOL (Biological study)
(parallel synthesis of aminoalkyl- or amidoalkyl-substituted aromatic amides as selective and neutral factor Xa inhibitors)
RN 745021-03-8 CAPLUS
CN Butanediamide, N1-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-N4-(5-bromo-2-pyridinyl)-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



L9 ANSWER 16 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:498571 CAPLUS
DOCUMENT NUMBER: 141:218300
TITLE: Structure-based design of amidinophenylurea-derivatives for factor VIIa inhibition
AUTHOR(S): Klingler, Otmar; Matter, Hans; Schudok, Manfred; Donghi, Monica; Czech, Joerg; Lorenz, Martin; Nestler, Hans Peter; Szillat, Hauke; Schreuder, Herman
CORPORATE SOURCE: Aventis Pharma Deutschland GmbH, Frankfurt, D-65926, Germany
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(14), 3715-3720
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:218300
IT 745031-07-6P 745031-17-8P 745031-18-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(structure-based design of amidinophenylurea-derivs. for factor VIIa inhibition)
RN 745031-07-6 CAPLUS
CN Acetamide, 2-[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[1-[4-(4-morpholinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 745031-17-8 CAPLUS
CN Acetamide, 2-[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[1-[3-bromo-4-(4-morpholinyl)phenyl]ethyl]- (CA INDEX NAME)



RN 745031-18-9 CAPLUS
CN Acetamide, 2-[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[1-[4-(4-morpholinyl)-3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 17 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:403758 CAPLUS
DOCUMENT NUMBER: 141:150454
TITLE: Identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis
AUTHOR(S): Shuttleworth, Stephen J.; Lizarzaburu, Mike E.; Chai, Anne; Coward, Peter
CORPORATE SOURCE: Tularik Inc., Department of Chemistry, South San Francisco, CA, 94080, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (2004), 14(12), 3037-3042
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:150454
IT 185215-75-2, PD165929
RL: PAC (Pharmacological activity); BIOL (Biological study)
(identification and optimization of novel partial agonists of Neuromedin B receptor using parallel synthesis of 3-amino-2,3,4,9-tetrahydro-1H-carbazole-3-carboxylic acid amide analogs)
RN 185215-75-2 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 18 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:308415 CAPLUS
DOCUMENT NUMBER: 140:321240
TITLE: Preparation of lactam-containing diaminoalkanes, β-amino acids, α-amino acids and derivatives thereof as factor Xa inhibitors
INVENTOR(S): Qiao, Jennifer X.; Han, Wei
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 172 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004031145	A2	20040415	WO 2003-US31079	20031001
WO 2004031145	A3	20040701		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040077635	A1	20040422	US 2003-677063	20031001
AU 2003279735	A1	20040423	AU 2003-279735	20031001
EP 1558606	A2	20050803	EP 2003-773077	20031001
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20070129361	A1	20070607	US 2007-622484	20070112

PRIORITY APPLN. INFO.:

US 2002-415366P	P	20021002
US 2002-417208P	P	20021009
US 2003-677063	A1	20031001
WO 2003-US31079	W	20031001

OTHER SOURCE(S): MARPAT 140:321240

IT 678174-81-7P 678177-49-6P 678177-92-9P
678177-93-0P 678178-00-2P 678178-01-3P
678178-02-4P 678178-03-5P 678178-04-6P
678178-05-7P 678178-06-8P 678178-07-9P
678178-08-0P 678178-09-1P 678178-10-4P
678178-11-5P 678178-18-2P 678178-19-3P
678178-20-6P 678178-21-7P 678178-23-9P
678178-25-1P 678178-27-3P 678178-29-5P
678178-30-8P 678178-31-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of lactam-containing diaminoalkanes, β-amino acids, α-amino acids and derivs. thereof as factor Xa inhibitors for treating thromboembolic disorder)

RN 678174-81-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678177-49-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678177-92-9 CAPLUS
CN Benzo[b]thiophene-2-acetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678177-93-0 CAPLUS
CN Benzo[b]thiophene-2-acetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-00-2 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-01-3 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-02-4 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-03-5 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-04-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-05-7 CAPLUS
CN Benzenebutanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-06-8 CAPLUS
CN Propanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-07-9 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-08-0 CAPLUS
CN Pentanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-09-1 CAPLUS
CN Pentanamide, 5-amino-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-10-4 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 678178-11-5 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylsulfonyl)-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-18-2 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-19-3 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-20-6 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-21-7 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-23-9 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-25-1 CAPLUS
CN Benzenebutanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-27-3 CAPLUS
CN Propanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-29-5 CAPLUS
CN Butanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-30-8 CAPLUS
CN Pentanediamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



RN 678178-31-9 CAPLUS
CN Pentanamide, 5-amino-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyridinyl)phenyl]- (CA INDEX NAME)



L9 ANSWER 19 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:252476 CAPLUS
DOCUMENT NUMBER: 140:287179
TITLE: Preparation of [phenylureido(hetero)cyclyl]carboxamides as inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
INVENTOR(S): Bolton, Gary Louis; Filipski, Kevin James; Kohrt, Jeffrey Thomas; La, Frances Thu; Leonard, Daniele Marie
PATENT ASSIGNEE(S): Warner-Lambert Company Llc, USA
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004024679	A1	20040325	WO 2003-IB3900		20030902
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2497003	A1	20040325	CA 2003-2497003		20030902
AU 2003260821	A1	20040430	AU 2003-260821		20030902
EP 1539686	A1	20050615	EP 2003-795154		20030902
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
BR 2003014219	A	20050719	BR 2003-14219		20030902
JP 2005538175	T	20051215	JP 2004-535772		20030902
US 20040167131	A1	20040826	US 2003-662046		20030911
MX 2005PA02703	A	20050505	MX 2005-PA2703		20050310
PRIORITY APPLN. INFO.:			US 2002-409891P	P	20020911
			WO 2003-IB3900	W	20030902

OTHER SOURCE(S): MARPAT 140:287179
IT 675833-75-7P, 2-[3-(4-Chlorophenyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]-2-methylpropionamide 675833-79-1P, 2-[3-(4-Chlorophenyl)ureido]-N-(3-fluoro-2'-sulfamoylbiphenyl-4-yl)-2-methylpropionamide 675833-89-3P, 2-[3-(4-Chlorophenyl)-1-methylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675833-96-2P, 2-[3-(4-Chlorophenyl)ureido]-3-hydroxy-2-hydroxymethyl-N-(2'-sulfamoylbiphenyl-4-yl)propionamide 675834-22-7P, 2-[3-(4-Chlorophenyl)-1-(cyclopropylmethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-25-0P

, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-26-1P, 2-[3-(4-Chlorophenyl)-1-isobutylureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-27-2P, 2-[3-(4-Chlorophenyl)-1-(2-dimethylaminoethyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-28-3P, 2-[1-Benzyl-3-(4-chlorophenyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-29-4P, 2-[3-(4-Chlorophenyl)-1-(4-methoxybenzyl)ureido]-N-[3-fluoro-2'-(methanesulfonyl)biphenyl-4-yl]acetamide 675834-30-7P, 2-[3-(4-Chlorophenyl)-1-(2-methoxyethyl)ureido]-N-[2-fluoro-4-(2-oxopiperidin-1-yl)phenyl]acetamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(factor Xa inhibitor; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)

RN 675833-75-7 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-methyl- (CA INDEX NAME)



RN 675833-79-1 CAPLUS
CN Propanamide, N-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-methyl- (CA INDEX NAME)



RN 675833-89-3 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]methylamino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675833-96-2 CAPLUS
CN Propanamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-hydroxy-2-(hydroxymethyl)- (CA INDEX

NAME)



RN 675834-22-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](cyclopropylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-25-0 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-26-1 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methylpropyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-27-2 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][2-(dimethylamino)ethyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)





RN 675834-28-3 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](phenylmethyl)amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-29-4 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl][(4-methoxyphenyl)methyl]amino]-N-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 675834-30-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl](2-methoxyethyl)amino]-N-[2-fluoro-4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



IT 675834-00-1P, N-[2'-(tert-Butylsulfamoyl)biphenyl-4-yl]-2-[3-(4-chlorophenyl)ureido]-3-hydroxy-2-hydroxymethylpropionamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of [phenylureido(hetero)cyclyl]carboxamides as factor Xa inhibitors for treatment of abnormal thrombosis)
RN 675834-00-1 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-3-hydroxy-2-(hydroxymethyl)- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 20 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:143100 CAPLUS
DOCUMENT NUMBER: 140:199315
TITLE: Preparation of iminothiazolidinone amino acid derivatives as inhibitors of HCV replication
INVENTOR(S): Romine, Jeffrey Lee; Martin, Scott W.; Snyder,

Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren; Lemm, Julie; O'Boyle, Donald; Gao, Min; Colonno, Richard

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 127 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014852	A2	20040219	WO 2003-US24717	20030808
WO 2004014852	A3	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003261434	A1	20040225	AU 2003-261434	20030808
US 20050069522	A1	20050331	US 2003-637156	20030808
US 20050096364	A1	20050505	US 2003-637099	20030808
US 7183302	B2	20070227		

PRIORITY APPLN. INFO.:

US 2002-402661P	P	20020812
US 2002-403694P	P	20020815
WO 2003-US24717	W	20030808

OTHER SOURCE(S): MARPAT 140:199315

IT 657414-06-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of iminothiazolidinone amino acid derivs. as inhibitors of HCV replication)

RN 657414-06-7 CAPLUS

CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L9 ANSWER 21 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:142910 CAPLUS
DOCUMENT NUMBER: 140:199742
TITLE: Preparation of iminothiazolidinone amino acid derivatives as combination pharmaceutical agents for use as inhibitors of HCV replication
INVENTOR(S): Colonno, Richard; Lemm, Julie; O'Boyle, Donald; Gao, Min; Romine, Jeffrey Lee; Martin, Scott W.; Snyder, Lawrence B.; Serrano-Wu, Michael; Deshpande, Milind; Whitehouse, Darren
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014313	A2	20040219	WO 2003-US25036	20030808
WO 2004014313	A3	20051215		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003264038	A1	20040225	AU 2003-264038	20030808
US 20050069522	A1	20050331	US 2003-637156	20030808
US 20050096364	A1	20050505	US 2003-637099	20030808
US 7183302	B2	20070227		

PRIORITY APPLN. INFO.:	US 2002-402661P	P	20020812
	US 2002-403694P	P	20020815
	WO 2003-US25036	W	20030808

OTHER SOURCE(S): MARPAT 140:199742
IT 657414-06-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of iminothiazolidinone amino acid derivs. as combination pharmaceutical agents for use as inhibitors of HCV replication)

RN 657414-06-7 CAPLUS

CN Propanamide, N-[4-[2-[(3-fluorophenyl)imino]-3-(2-furanylmethyl)-4-oxo-5-thiazolidinyl]phenyl]-2-[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



L9 ANSWER 22 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:2850 CAPLUS

DOCUMENT NUMBER: 140:77013

TITLE: Preparation of diphenylazetidinones for the treatment of hyperlipidemia, arteriosclerosis and hypercholesterolemia

INVENTOR(S): Jaehne, Gerhard; Frick, Wendelin; Flohr, Stefanie; Lindenschmidt, Andreas; Glombik, Heiner; Kramer, Werner; Heuer, Hubert; Schaefer, Hans-Ludwig

PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany

SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004000804	A1	20031231	WO 2003-EP5815	20030604

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

DE 10227506	A1	20040108	DE 2002-10227506	20020619
CA 2490109	A1	20031231	CA 2003-2490109	20030604
AU 2003242616	A1	20040106	AU 2003-242616	20030604
EP 1517892	A1	20050330	EP 2003-760591	20030604
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003011940	A	20050405	BR 2003-11940	20030604
CN 1662493	A	20050831	CN 2003-814087	20030604
NZ 537304	A	20051028	NZ 2003-537304	20030604
JP 2005533072	T	20051104	JP 2004-514660	20030604
RU 2315754	C2	20080127	RU 2005-101091	20030604
US 20040082561	A1	20040429	US 2003-463807	20030618
US 7176194	B2	20070213		
MX 2004PA12236	A	20050225	MX 2004-PA12236	20041207
IN 2004CN02826	A	20060210	IN 2004-CN2826	20041214
NO 2005000073	A	20050106	NO 2005-73	20050106
ZA 2004009381	A	20060531	ZA 2004-9831	20060403
US 20060270613	A1	20061130	US 2006-501758	20060810
US 20070037787	A1	20070215	US 2006-544746	20061010
US 20070043017	A1	20070222	US 2006-544718	20061010
US 7390790	B2	20080624		

PRIORITY APPLN. INFO.:	DE 2002-10227506	A	20020619
	US 2002-411984P	P	20020919
	WO 2003-EP5815	W	20030604
	US 2003-463807	A1	20030618

OTHER SOURCE(S): MARPAT 140:77013

IT 640333-25-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(target compound; preparation of diphenylazetidinones for the treatment of hyperlipidemia, arteriosclerosis and hypercholesterolemia)

RN 640333-25-1 CAPLUS

CN Acetamide, 2-[[[[4-(aminoiminomethyl)phenyl]amino]carbonyl]amino]-N-[[4-[3-[3-(4-fluorophenyl)-3-hydroxypropyl]-2-(4-methoxyphenyl)-4-oxo-1-azetidinyl]phenyl]methyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 640333-24-0

CMF C36 H37 F N6 O5



CM 2

CRN 76-05-1
CMF C2 H F3 O2



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 23 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:892749 CAPLUS
DOCUMENT NUMBER: 139:381378
TITLE: Preparation of carboxylic acid amides as inhibitors of blood-coagulation factor Xa and VIIa
INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Gleitz, Johannes; Cezanne, Bertram; Tsaklakidis, Christos; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 79 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003093235	A1	20031113	WO 2003-EP3331	20030331
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10218974	A1	20031127	DE 2002-10218974	20020427
DE 10236868	A1	20040226	DE 2002-10236868	20020812
CA 2483228	A1	20031113	CA 2003-2483228	20030331
AU 2003226755	A1	20031117	AU 2003-226755	20030331
EP 1499591	A1	20050126	EP 2003-747402	20030331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005531547	T	20051020	JP 2004-501374	20030331
US 20050171154	A1	20050804	US 2004-512478	20041026
US 7183277	B2	20070227		

PRIORITY APPLN. INFO.:
DE 2002-10218974 A 20020427
DE 2002-10236868 A 20020812
WO 2003-EP3331 W 20030331

OTHER SOURCE(S): MARPAT 139:381378
IT 625102-16-1P 625102-18-3P 625102-20-7P
625102-30-9P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of carboxylic acid amides as inhibitors of blood-coagulation factor Xa and VIIa)

RN 625102-16-1 CAPLUS

CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-methyl-4-(2-thioxo-1-pyrrolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-18-3 CAPLUS

CN 2H-Pyrrolium, 1-[4-[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-phenylacetyl]amino]-2-methylphenyl]-3,4-dihydro-5-(methylthio)-, iodide (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-20-7 CAPLUS

CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-30-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 625102-22-9P 625102-24-1P 625102-26-3P
625102-28-5P 625102-32-1P 625102-34-3P
625102-36-5P 625102-38-7P 625102-40-1P
625102-42-3P 625102-43-4P 625102-46-7P
625102-49-0P 625102-64-9P 625102-66-1P
625102-67-2P 625102-69-4P 625102-70-7P
625102-72-9P 625102-73-0P 625102-75-2P
625102-76-3P 625102-78-5P 625102-79-6P
625102-81-0P 625102-82-1P 625102-86-5P
625102-88-7P 625102-90-1P 625102-91-2P
625102-93-4P 625102-94-5P 625102-96-7P
625102-97-8P 625102-99-0P 625103-00-6P
625103-02-8P 625103-03-9P 625103-05-1P
625103-06-2P 625103-08-4P 625103-09-5P
625103-11-9P 625103-12-0P 625103-14-2P
625103-15-3P 625103-16-4P 625103-17-5P
625103-19-7P 625103-20-0P 625103-22-2P
625103-23-3P 625103-25-5P 625103-26-6P
625103-28-8P 625103-29-9P 625103-31-3P
625103-34-6P 625103-36-8P 625103-37-9P
625103-39-1P 625103-40-4P 625103-42-6P

625103-43-7P 625103-68-6P 625103-70-0P
625103-72-2P 625103-74-4P 625103-77-7P
625103-80-2P 625103-82-4P 625103-85-7P
625103-87-9P 625104-13-4P 625104-18-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of carboxylic acid amides as inhibitors of blood-coagulation factor Xa and VIIa)

RN 625102-22-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 625102-24-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)-3-methylphenyl]-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 625102-26-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(methoxyimino)-1-piperidinyl]-3-methylphenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625102-28-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(methoxyimino)-1-pyrrolidinyl]phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625102-32-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 625102-34-3 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 625102-36-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-38-7 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-40-1 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)-3-methylphenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-42-3 CAPLUS
CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-43-4 CAPLUS
CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-42-3
CMF C23 H23 Cl N6 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-46-7 CAPLUS
CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-45-6
CMF C25 H25 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-49-0 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-48-9
CMF C22 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-64-9 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chloro-2-methylphenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-66-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-67-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (αR)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-66-1
CMF C26 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 625102-69-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-70-7 CAPLUS

CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (αS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-69-4
CMF C25 H24 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



RN 625102-72-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-73-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (αS)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-72-9
CMF C26 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



RN 625102-75-2 CAPLUS

CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-76-3 CAPLUS
CN 2-Thiopheneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-75-2
CMF C22 H21 Cl N6 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-78-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-5-methyl-1,3,4-thiadiazol-3(2H)-yl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-79-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-5-methyl-1,3,4-thiadiazol-3(2H)-yl)phenyl]-, (αR)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-78-5
CMF C24 H21 Cl N6 O2 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-81-0 CAPLUS
CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-82-1 CAPLUS
CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-81-0
CMF C24 H23 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-86-5 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-88-7 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625102-90-1 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-91-2 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-90-1
CMF C21 H25 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-93-4 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625102-94-5 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-93-4
CMF C22 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-96-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 625102-97-8 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625102-96-7
CMF C19 H20 Cl N5 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625102-99-0 CAPLUS

CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 625103-00-6 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625102-99-0
CMF C20 H20 Cl N7 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-02-8 CAPLUS
CN Propanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-03-9 CAPLUS
CN Propanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-02-8
CMF C19 H21 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-05-1 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625103-06-2 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625103-05-1
CMF C21 H22 Cl N7 O2

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-08-4 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-09-5 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-08-4
CMF C20 H22 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-11-9 CAPLUS
CN Butanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-12-0 CAPLUS
CN Butanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-11-9
CMF C21 H25 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-14-2 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625103-15-3 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-3-methyl-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625103-14-2
CMF C23 H26 Cl N7 O2

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-16-4 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-17-5 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-16-4
CMF C22 H26 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-19-7 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-20-0 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)phenyl]-2-[[[(4-

chlorophenyl)amino]carbonyl]amino]-4-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-19-7
CMF C22 H27 Cl N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-22-2 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-4-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625103-23-3 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-4-methyl-, (2R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 625103-22-2
CMF C24 H28 Cl N7 O2

Absolute stereochemistry.
Double bond geometry unknown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-25-5 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-4-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-26-6 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-4-methyl-, (2R)-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-25-5
CMF C23 H28 Cl N5 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-28-8 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 625103-29-9 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-28-8
CMF C21 H24 Cl N5 O3

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-31-3 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-3-methoxy- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 625103-34-6 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-1-methyl-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-33-5
CMF C24 H24 Cl N9 O2

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-36-8 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy- (CA INDEX NAME)



RN 625103-37-9 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(5-ethyl-2-imino-1,3,4-thiadiazol-3(2H)-yl)phenyl]-3-methoxy-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-36-8
CMF C21 H23 Cl N6 O3 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-39-1 CAPLUS
CN 1,3,4-Thiadiazole-2-carboxamide, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino- (CA INDEX NAME)



RN 625103-40-4 CAPLUS
CN 1,3,4-Thiadiazole-2-carboxamide, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-39-1
CMF C20 H20 Cl N7 O4 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-42-6 CAPLUS
CN 1,3,4-Thiadiazole-2-carboxylic acid, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, ethyl ester (CA INDEX NAME)



RN 625103-43-7 CAPLUS
CN 1,3,4-Thiadiazole-2-carboxylic acid, 4-[4-[[2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methoxy-1-oxopropyl]amino]phenyl]-4,5-dihydro-5-imino-, ethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 625103-42-6
CMF C22 H23 Cl N6 O5 S



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 625103-68-6 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-70-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(2-imino-1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-72-2 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-74-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-77-7 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-pyrrolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-80-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625103-82-4 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoimino)-3-methyl-1-imidazolidinyl]phenyl]-, (αR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.



RN 625103-85-7 CAPLUS
CN Benzeneacetamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625103-87-9 CAPLUS
CN Pentanamide, N-[4-(2-amino-4,5-dihydro-1H-imidazol-1-yl)-3-methylphenyl]-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625104-13-4 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-[2-(cyanoamino)-4,5-dihydro-1H-imidazol-1-yl]phenyl]-1-methyl-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 625104-18-9 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-imino-1-piperidinyl)phenyl]-4-(methylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 24 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:598507 CAPLUS
DOCUMENT NUMBER: 140:70458
TITLE: Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells
AUTHOR(S): Moody, Terry W.; Leyton, Julius; Garcia-Marin, Luis; Jensen, Robert T.
CORPORATE SOURCE: Center for Cancer Research, Office of the Director, National Cancer Institute, Department of Health and Human Services, National Institutes of Health, Bethesda, MD, 20892, USA
SOURCE: European Journal of Pharmacology (2003), 474(1), 21-29
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204066-82-0, PD168368 204067-01-6, PD176252
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells)
RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 25 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:376636 CAPLUS
DOCUMENT NUMBER: 138:385436
TITLE: Preparation of 4-(1,1-dioxido-2-isothiazolidinyl)benzenamines as inhibitors of blood-coagulation factor Xa for the treatment of thromboembolic diseases
INVENTOR(S): Dorsch, Dieter; Cezanne, Bertram; Tsaklakidis, Christos; Mederski, Werner; Gleitz, Johannes; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent Gmbh, Germany
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039543	A1	20030515	WO 2002-EP11349	20021010
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10155075	A1	20030522	DE 2001-10155075	20011109
CA 2465713	A1	20030515	CA 2002-2465713	20021010
AU 2002363366	A1	20030519	AU 2002-363366	20021010
AU 2002363366	B2	20071122		
EP 1441726	A1	20040804	EP 2002-802623	20021010
EP 1441726	B1	20061220		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK

BR 2002013680	A	20041026	BR 2002-13680		20021010
HU 2004001983	A2	20050128	HU 2004-1983		20021010
CN 1582148	A	20050216	CN 2002-821919		20021010
JP 2005522412	T	20050728	JP 2003-541834		20021010
AT 348611	T	20070115	AT 2002-802623		20021010
RU 2301228	C2	20070620	RU 2004-117594		20021010
ES 2277623	T3	20070716	ES 2002-802623		20021010
MX 2004PA04307	A	20040811	MX 2004-PA4307		20040506
US 20040254175	A1	20041216	US 2004-495254		20040510
US 7199133	B2	20070403			
ZA 2004004549	A	20050204	ZA 2004-4549		20040608
PRIORITY APPLN. INFO.:			DE 2001-10155075	A	20011109
			WO 2002-EP11349	W	20021010

OTHER SOURCE(S): MARPAT 138:385436

IT 524957-17-3P 524957-18-4P 524957-19-5P
524957-38-8P 524957-39-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of isothiazolidinylbenzenamines as inhibitors of blood coagulation factor Xa for the treatment of thromboembolic diseases)

RN 524957-17-3 CAPLUS

CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)



PAGE 2-A



RN 524957-18-4 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 524957-19-5 CAPLUS

CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 524957-38-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)-3-methylphenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 524957-39-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1,1-dioxido-2-isothiazolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 26 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:76556 CAPLUS
DOCUMENT NUMBER: 138:131125
TITLE: Fat accumulation-modulating compounds
INVENTOR(S): Stevenson, Michael John; Leighton, Harry Jefferson
PATENT ASSIGNEE(S): Adipogenix, Inc., USA
SOURCE: PCT Int. Appl., 96 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003007888	A2	20030130	WO 2002-US23295	20020722
WO 2003007888	A3	20031127		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002322585	A1	20030303	AU 2002-322585		20020722
US 20030144350	A1	20030731	US 2002-201588		20020722
PRIORITY APPLN. INFO.:			US 2001-306837P	P	20010720
			WO 2002-US23295	W	20020722

OTHER SOURCE(S): MARPAT 138:131125
IT 491868-51-0
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(fat accumulation-modulating compds.)
RN 491868-51-0 CAPLUS
CN Benzenepropanamide, N-[1,1'-biphenyl]-2-yl-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



L9 ANSWER 27 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:869567 CAPLUS
DOCUMENT NUMBER: 137:370356
TITLE: Preparation and use of bombesin receptor antagonists for treatment of sexual dysfunction in males and females
INVENTOR(S): Gonzalez, Maria Isabel; Higginbottom, Michael; Stock, Herman Thijs; Pritchard, Martyn Clive; Pinnock, Robert Denham; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Wayman, Christopher Peter
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 105 pp., Cont.-in-part of U.S. Pat. Appl. 2002 58,606.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 20020169101	A1	20021114	US 2001-999284		20011115
US 20020058606	A1	20020516	US 2001-759777		20010112
ZA 2003003249	A	20040623	ZA 2003-3249		20030425
PRIORITY APPLN. INFO.:			US 1999-133355P	P	19990510
			WO 2000-GB1787	W	20000510
			US 2000-700165	A2	20001109
			US 2001-759777	A2	20010112
			GB 2001-9910	A	20010423
			GB 2001-11037	A	20010504

OTHER SOURCE(S): MARPAT 137:370356

IT 204067-01-6 428864-38-4
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of as bombesin receptor antagonists for treatment of sexual dysfunction)
RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 428864-38-4 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(4-aminophenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 204066-82-0 204066-83-1 204066-84-2
204066-89-7 204066-95-5 428864-51-1
428864-54-4 428864-57-7 428864-58-8

475247-11-1 475247-13-3 475247-25-7
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of as bombesin receptor antagonists for treatment of sexual dysfunction)

RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-83-1 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-84-2 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-89-7 CAPLUS
CN Benzenepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 204066-95-5 CAPLUS
CN 1H-Imidazole-5-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 428864-51-1 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(2-phenylcyclohexyl)- (CA INDEX NAME)



RN 428864-54-4 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 428864-57-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 428864-58-8 CAPLUS
CN Benzenepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-2-nitro-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 475247-11-1 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)



RN 475247-13-3 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]methylamino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 475247-25-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl- (CA INDEX NAME)



L9 ANSWER 28 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:695975 CAPLUS
DOCUMENT NUMBER: 137:232913
TITLE: Preparation of peptides for pharmaceutical use as modulators of melanocortin receptors
INVENTOR(S): Yu, Guixue; Macor, John; Herpin, Timothy; Lawrence, R. Michael; Morton, George C.; Ruel, Rejean; Poindexter, Graham S.; Ruediger, Edward H.; Thibault, Carl
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 107 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002070511	A1	20020912	WO 2002-US6479	20020302
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2437594	A1	20020912	CA 2002-2437594	20020302
AU 2002254095	A1	20020919	AU 2002-254095	20020302
EP 1363898	A1	20031126	EP 2002-723310	20020302
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2004001544	A2	20041228	HU 2004-1544	20020302
JP 2005511475	T	20050428	JP 2002-569831	20020302
US 20030092732	A1	20030515	US 2002-90582	20020304
US 6979691	B2	20051227		
US 20030096827	A1	20030522	US 2002-90288	20020304
US 6713487	B2	20040330		
US 20040229882	A1	20041118	US 2003-696761	20031029
US 7067525	B2	20060627		
US 20060025403	A1	20060202	US 2005-199464	20050808
PRIORITY APPLN. INFO.:			US 2001-273206P P	20010302
			US 2001-273291P P	20010302

WO 2002-US6479	W	20020302
US 2002-90288	A3	20020304
US 2002-90582	A3	20020304

OTHER SOURCE(S): MARPAT 137:232913

IT 457894-44-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptides for pharmaceutical use as modulators of melanocortin receptors)

RN 457894-44-9 CAPLUS

CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 29 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:695727 CAPLUS

DOCUMENT NUMBER: 137:226646

TITLE: Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-AMP associated disorders

INVENTOR(S): Macor, John E.; Carlson, Kenneth E.

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 91 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002069905	A2	20020912	WO 2002-US6805	20020304
WO 2002069905	A3	20031009		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,

KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2439691	A1	20020912	CA 2002-2439691		20020304
AU 2002245601	A1	20020919	AU 2002-245601		20020304
US 20030069169	A1	20030410	US 2002-90258		20020304
EP 1370211	A2	20031217	EP 2002-713772		20020304
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
JP 2005506286	T	20050303	JP 2002-569083		20020304
HU 2006000103	A2	20060628	HU 2006-103		20020304
US 20040229882	A1	20041118	US 2003-696761		20031029
US 7067525	B2	20060627			
US 20060025403	A1	20060202	US 2005-199464		20050808
PRIORITY APPLN. INFO.:			US 2001-273206P	P	20010302
			US 2001-273291P	P	20010302
			US 2001-289719P	P	20010509
			US 2002-90288	A3	20020304
			US 2002-90582	A3	20020304
			WO 2002-US6805	W	20020304

OTHER SOURCE(S): MARPAT 137:226646

IT 457894-44-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Co-administration of melanocortin receptor agonist and cAMP phosphodiesterase inhibitor for treatment of cAMP-associated disorders)

RN 457894-44-9 CAPLUS

CN 1H-Imidazole-4-propanamide, N-[(1R)-1-[(4-methoxyphenyl)methyl]-2-oxo-2-[4-(1-oxobutyl)-4-phenyl-1-piperidinyl]ethyl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 30 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:487398 CAPLUS

DOCUMENT NUMBER: 137:41784

TITLE: Nonpeptide bombesin receptor antagonists for treatment and diagnosis of anxiety, panic disorders, cancers, ulcers, and other conditions

INVENTOR(S): Pinnock, Robert Denham; Pritchard, Martyn Clive

PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Lucas, Brian Ronald

SOURCE: PCT Int. Appl., 48 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049644	A1	20020627	WO 2000-GB4915	20001220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2432066	A1	20020627	CA 2000-2432066	20001220
AU 2001023816	A	20020701	AU 2001-23816	20001220
EP 1343498	A1	20030917	EP 2000-987567	20001220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002496	A2	20031229	HU 2003-2496	20001220
BR 2000017393	A	20040203	BR 2000-17393	20001220
ZA 2003003723	A	20040514	ZA 2003-3723	20030514
MX 2003PA05567	A	20031006	MX 2003-PA5567	20030619

PRIORITY APPLN. INFO.: WO 2000-GB4915 W 20001220
OTHER SOURCE(S): MARPAT 137:41784
IT 204067-01-6
RL: DGN (Diagnostic use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nonpeptide bombesin receptor antagonists for treatment and diagnosis of anxiety, panic disorders, cancers, ulcers, and other conditions)
RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 31 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:465965 CAPLUS
DOCUMENT NUMBER: 137:47128
TITLE: Preparation of of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders and tumors.
INVENTOR(S): Dorsch, Dieter; Mederski, Werner; Tsaklakidis, Christos; Cezanne, Bertram; Gleitz, Johannes; Barnes, Christopher
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 92 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048099	A1	20020620	WO 2001-EP13545	20011121
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10063008	A1	20020620	DE 2000-10063008	20001216
CA 2431766	A1	20020620	CA 2001-2431766	20011121
AU 2002021881	A	20020624	AU 2002-21881	20011121
EP 1341755	A1	20030910	EP 2001-270524	20011121
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016115	A	20031223	BR 2001-16115	20011121
HU 2003003296	A2	20040128	HU 2003-3296	20011121
HU 2003003296	A3	20060428		
JP 2004515538	T	20040527	JP 2002-549632	20011121
NO 2003002695	A	20030613	NO 2003-2695	20030613
MX 2003PA05342	A	20031006	MX 2003-PA5342	20030613
US 20040038858	A1	20040226	US 2003-450651	20030616
IN 2003KN00896	A	20050311	IN 2003-KN896	20030714
ZA 2003005455	A	20040826	ZA 2003-5455	20030715
US 20050137230	A1	20050623	US 2005-59655	20050217

PRIORITY APPLN. INFO.:
DE 2000-10063008 A 20001216
WO 2001-EP13545 W 20011121
US 2003-450651 A3 20030616

OTHER SOURCE(S): MARPAT 137:47128
IT 438053-48-6P 438053-49-7P 438053-51-1P
438053-52-2P 438053-53-3P 438053-54-4P
438053-55-5P 438053-56-6P 438053-57-7P
438053-58-8P 438053-62-4P 438053-64-6P
438053-65-7P 438053-66-8P 438053-67-9P
438053-68-0P 438053-69-1P 438053-70-4P
438053-71-5P 438053-72-6P 438053-73-7P
438053-74-8P 438053-75-9P 438053-76-0P
438053-77-1P 438053-78-2P 438053-79-3P
438053-80-6P 438053-81-7P 438053-82-8P
438053-83-9P 438053-84-0P 438053-85-1P
438053-87-3P 438053-88-4P 438053-89-5P
438053-90-8P 438053-91-9P 438053-92-0P

438053-93-1P 438053-94-2P 438053-95-3P
438053-96-4P 438053-97-5P 438053-98-6P
438053-99-7P 438054-00-3P 438054-01-4P
438054-02-5P 438054-03-6P 438054-04-7P
438054-05-8P 438054-06-9P 438054-07-0P
438054-08-1P 438054-09-2P 438054-10-5P
438054-11-6P 438054-12-7P 438054-13-8P
438054-14-9P 438054-15-0P 438054-16-1P
438054-17-2P 438054-18-3P 438054-19-4P
438054-20-7P 438054-21-8P 438054-22-9P
438054-23-0P 438054-24-1P 438054-25-2P
438054-26-3P 438054-27-4P 438054-29-6P
438054-30-9P 438054-31-0P 438054-32-1P
438054-33-2P 438054-34-3P 438054-35-4P
438054-36-5P 438054-37-6P 438054-38-7P
438054-39-8P 438054-40-1P 438054-42-3P
438054-43-4P 438054-44-5P 438054-45-6P
438054-46-7P 438054-47-8P 438054-48-9P
438054-49-0P 438054-50-3P 438054-51-4P
438054-52-5P 438054-53-6P 438054-54-7P
438054-59-2P 438054-60-5P 438054-61-6P
438054-62-7P 438054-63-8P 438054-73-0P
438054-74-1P 438054-75-2P 438054-76-3P
438054-77-4P 438054-78-5P 438054-79-6P
438054-80-9P 438054-99-0P 438055-00-6P
438055-01-7P 438055-02-8P 438055-03-9P
438055-04-0P 438055-06-2P 438055-58-4P
438055-59-5P 438055-60-8P 438055-61-9P
438055-62-0P 438055-63-1P 438055-64-2P
438055-65-3P 438055-66-4P 438055-67-5P
438055-68-6P 438055-69-7P 438055-70-0P
438055-71-1P 438056-84-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compound; preparation of ureido- and carbamoyloxy-substituted amides
as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)

RN 438053-48-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-49-7 CAPLUS

CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-51-1 CAPLUS
CN Pentanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[(phenylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-52-2 CAPLUS
CN 2-Thiophenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-53-3 CAPLUS
CN 1H-Imidazole-5-propanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-54-4 CAPLUS
CN Hexanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[(phenylamino)carbonyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-55-5 CAPLUS
CN Butanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methylthio)-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-56-6 CAPLUS
CN Benzeneacetamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-57-7 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-58-8 CAPLUS
CN Benzenepropanamide, α-[[[(4-methylphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-62-4 CAPLUS
CN Pentanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-64-6 CAPLUS
CN 3-Pyridinepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-65-7 CAPLUS
CN 1H-Indole-3-propanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-66-8 CAPLUS
CN Propanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-

[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-67-9 CAPLUS
CN Acetamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438053-68-0 CAPLUS
CN Benzenepropanamide, α-[[[(3-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-69-1 CAPLUS
CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-70-4 CAPLUS
CN Benzenepropanamide, α-[[[(2-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-71-5 CAPLUS
CN Benzenepropanamide, α-[[[(4-ethoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-72-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-methylphenyl)amino]carbonyl]amino]-N-[2'-

(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-73-7 CAPLUS
CN Benzenepropanamide, α-[[[(2-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-74-8 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-2-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-75-9 CAPLUS
CN Benzenepropanamide, α-[[[(3-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-76-0 CAPLUS
CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-77-1 CAPLUS
CN Benzenepropanamide, α-[[[(2-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-78-2 CAPLUS
CN Benzenepropanamide, α-[[[(4-ethoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-79-3 CAPLUS
CN Benzenepropanamide, α-[[[(2-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-80-6 CAPLUS
CN Benzoic acid, 4-[[[[(1R)-2-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-2-oxo-1-(phenylmethyl)ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-81-7 CAPLUS
CN Carbamic acid, [5-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]amino]-5-oxo-4-[[(phenylamino)carbonyl]amino]pentyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 438053-82-8 CAPLUS
CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-83-9 CAPLUS
CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[(phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-84-0 CAPLUS
CN Cyclopropanepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-85-1 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 438053-87-3 CAPLUS
CN Benzenepropanamide, α-[[[(4-bromophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-88-4 CAPLUS
CN Benzenepropanamide, α-[[[(3-fluoro-4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-89-5 CAPLUS

CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]- (CA INDEX NAME)



RN 438053-90-8 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-91-9 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-92-0 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-93-1 CAPLUS
CN Benzenepropanamide, α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-94-2 CAPLUS
CN Benzenepropanamide, α-[[[(4-bromophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-95-3 CAPLUS

CN Benzenepropanamide, α-[[[(4-iodophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-96-4 CAPLUS
CN Benzenepropanamide, α-[[[(4-fluorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-97-5 CAPLUS
CN Benzenepropanamide, α-[[[(3-fluoro-4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-98-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438053-99-7 CAPLUS
CN Benzenepropanamide, α-[[[(4-iodophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-00-3 CAPLUS
CN Benzenepropanamide, α-[[[(4-fluorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-01-4 CAPLUS
CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-02-5 CAPLUS
CN Benzenepropanamide, N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-03-6 CAPLUS
CN Pentanamide, 5-amino-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438054-04-7 CAPLUS
CN Benzenepropanamide, N-[4-(4-morpholinyl)phenyl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-05-8 CAPLUS
CN Pentanamide, N-[4-(4-morpholinyl)phenyl]-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438054-06-9 CAPLUS
CN Benzenepropanamide, N-[4-(4-morpholinyl)phenyl]-α-[[(phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-07-0 CAPLUS
CN Benzenepropanamide, 3-cyano-N-[4-(4-morpholinyl)phenyl]-α-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438054-08-1 CAPLUS
CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 438054-09-2 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylthio)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)



RN 438054-10-5 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-11-6 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[4-(4-morpholinyl)phenyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-12-7 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[4-(4-morpholinyl)phenyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-13-8 CAPLUS
CN Benzenepropanamide, α-[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-14-9 CAPLUS
CN Benzenepropanamide, α-[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-15-0 CAPLUS
CN Pentanamide, 2-[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-16-1 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-17-2 CAPLUS
CN Hexanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-18-3 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-(methylthio)-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-19-4 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-20-7 CAPLUS
CN 2-Thiophenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-21-8 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-22-9 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-23-0 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-24-1 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-25-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-26-3 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-27-4 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-methyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-29-6 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3,3-trifluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-30-9 CAPLUS
CN 2-Pyridineacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-31-0 CAPLUS

CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-32-1 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-3,3-dimethyl-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-33-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-2-fluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-34-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-fluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-35-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-fluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-36-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-hydroxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-37-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-4-hydroxy-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-38-7 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438054-39-8 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-40-1 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-42-3 CAPLUS
CN Benzenepropanamide, N-([1,1'-biphenyl]-2-ylmethyl)-α-[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-43-4 CAPLUS
CN Benzenepropanamide, N-([1,1'-biphenyl]-2-ylmethyl)-α-[[(phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-44-5 CAPLUS
CN Pentanamide, N-([1,1'-biphenyl]-2-ylmethyl)-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438054-45-6 CAPLUS
CN Benzenepropanamide, N-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-α-[[(phenylamino)carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-46-7 CAPLUS
CN Benzenepropanamide, N-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-α-[[(phenylamino)carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-47-8 CAPLUS
CN Pentanamide, N-[[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]methyl]-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438054-48-9 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-49-0 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-50-3 CAPLUS
CN Pentanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]- (CA INDEX NAME)



RN 438054-51-4 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-52-5 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-[[(1,1-dimethylethyl)amino]sulfonyl][1,1'-biphenyl]-4-yl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-53-6 CAPLUS
CN Benzenepropanamide, N-[2'-(aminosulfonyl)[1,1'-biphenyl]-4-yl]-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-54-7 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-59-2 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-60-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(tetrahydro-2H-pyran-4-yl)-4-piperidinyl]methyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-61-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-

(2-oxo-1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-62-7 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-63-8 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(3-oxo-4-morpholinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-73-0 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-74-1 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-75-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclopentyl-4-piperidinyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-76-3 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-77-4 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-78-5 CAPLUS

CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-79-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-80-9 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperidinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438054-99-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-00-6 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-01-7 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-02-8 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-03-9 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-04-0 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-06-2 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-58-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438055-59-5 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-4,4,4-trifluoro-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438055-60-8 CAPLUS
CN Benzenepropanamide, 4-cyano-N-[4-(2-oxo-1-piperidinyl)phenyl]-α-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438055-61-9 CAPLUS
CN Benzenepropanamide, 4-cyano-α-[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438055-62-0 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-3-cyano-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438055-63-1 CAPLUS
CN Benzenepropanamide, 3-(aminocarbonyl)-N-[4-(2-oxo-1-piperidinyl)phenyl]-α-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 438055-64-2 CAPLUS
CN Benzenepropanamide, 3-(aminocarbonyl)-α-[[(phenylamino)carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438055-65-3 CAPLUS
CN Benzenepropanamide, 3-(aminocarbonyl)-α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]- (CA INDEX NAME)



RN 438055-66-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-67-5 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3-methyl-4-(2-oxo-1-piperidinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-68-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-

oxo-1-piperazinyl)phenyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 438055-69-7 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (CA INDEX NAME)



RN 438055-70-0 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 438055-71-1 CAPLUS
CN 2-Thiopheneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(2-oxo-1(2H)-pyrazinyl)phenyl]- (CA INDEX NAME)



RN 438056-84-9 CAPLUS
CN Butanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-4-(methylthio)- (CA INDEX NAME)



IT 438055-73-3P 438055-74-4P 438055-75-5P
438055-87-9P 438055-88-0P 438055-89-1P
438055-90-4P 438055-91-5P 438055-92-6P
438055-93-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of ureido- and carbamoyloxy-substituted amides as inhibitors of factor Xa for the treatment of clotting disorders such as strokes and cancer)

RN 438055-73-3 CAPLUS
CN Pentanamide, 5-amino-N-[2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-[[(phenylamino)carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)



RN 438055-74-4 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, hydrochloride (1:?), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 438055-75-5 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[1-(4-pyridinyl)-4-piperidinyl]-, hydrochloride (1:?), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



● x HCl

RN 438055-87-9 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[(2R)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 438055-88-0 CAPLUS
CN 1-Piperazinecarboxylic acid, 4-[4-[[(2S)-2-[[[(4-chlorophenyl)amino]carbonyl]amino]-1-oxo-3-phenylpropyl]amino]phenyl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 438055-89-1 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:?), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 438055-90-4 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:?), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



●x HCl

RN 438055-91-5 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, hydrochloride (1:1), (αS)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 438055-92-6 CAPLUS
CN Benzenepropanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 438055-93-7 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(1-cyclohexyl-4-piperidinyl)-, hydrochloride (1:1), (αR)- (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 32 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:391535 CAPLUS
DOCUMENT NUMBER: 136:380143
TITLE: Treatment of sexual dysfunction using bombesin antagonist
INVENTOR(S): Gonzalez, Maria Isabel; Higginbottom, Michael; Pinnock, Robert Denham; Pritchard, Martyn Clive; Stock, Herman Thijs
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 151 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002040022	A1	20020523	WO 2000-GB4380	20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2426521	A1	20020523	CA 2000-2426521	20001117
AU 2001014046	A	20020527	AU 2001-14046	20001117
EP 1333829	A1	20030813	EP 2000-976165	20001117
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2000017374	A	20030930	BR 2000-17374	20001117
HU 2003003500	A2	20040128	HU 2003-3500	20001117
JP 2004525864	T	20040826	JP 2002-542395	20001117
CA 2429106	A1	20020523	CA 2001-2429106	20011114
WO 2002040008	A2	20020523	WO 2001-GB5018	20011114

WO 2002040008		A3	20020822		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002023802		A	20020527	AU 2002-23802	20011114
EP 1333824		A2	20030813	EP 2001-994552	20011114
EP 1333824		B1	20050907		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001015364		A	20030923	BR 2001-15364	20011114
HU 2003001892		A2	20031128	HU 2003-1892	20011114
HU 2003001892		A3	20050628		
JP 2004522710		T	20040729	JP 2002-542382	20011114
CN 1518445		A	20040804	CN 2001-821951	20011114
NZ 525415		A	20041126	NZ 2001-525415	20011114
AT 303804		T	20050915	AT 2001-994552	20011114
TW 220650		B	20040901	TW 2001-90128451	20011116
MX 2003PA03481		A	20040910	MX 2003-PA3481	20030416
MX 2003PA03482		A	20040910	MX 2003-PA3482	20030416
ZA 2003003250		A	20040426	ZA 2003-3250	20030425
US 20040087561		A1	20040506	US 2003-416934	20031204
PRIORITY APPLN. INFO.:				WO 2000-GB4380	W 20001117
				GB 2001-9910	A 20010423
				GB 2001-11037	A 20010504
				WO 2001-GB5018	W 20011114

IT 204067-01-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin antagonists for treatment of sexual dysfunction)

RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 33 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:391522 CAPLUS
DOCUMENT NUMBER: 136:395983
TITLE: Bombesin receptor antagonists, and combinations with other agents, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Stock, Herman Thijs; Pinnock, Robert Denham; Pritchard, Martyn Clive; Wayman, Christopher Peter; Van der Graaf, Pieter Hadewijn; Naylor, Alisdair Mark; Higginbottom, Michael
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: PCT Int. Appl., 225 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2002040008	A2	20020523	WO 2001-GB5018		20011114
WO 2002040008	A3	20020822			
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
WO 2002040022	A1	20020523	WO 2000-GB4380		20001117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
CA 2429106	A1	20020523	CA 2001-2429106		20011114
AU 2002023802	A	20020527	AU 2002-23802		20011114
EP 1333824	A2	20030813	EP 2001-994552		20011114
EP 1333824	B1	20050907			
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
BR 2001015364	A	20030923	BR 2001-15364		20011114
HU 2003001892	A2	20031128	HU 2003-1892		20011114
HU 2003001892	A3	20050628			
JP 2004522710	T	20040729	JP 2002-542382		20011114
NZ 525415	A	20041126	NZ 2001-525415		20011114
AT 303804	T	20050915	AT 2001-994552		20011114
MX 2003PA03482	A	20040910	MX 2003-PA3482		20030416
US 20040087561	A1	20040506	US 2003-416934		20031204
PRIORITY APPLN. INFO.:			WO 2000-GB4380	W	20001117
			GB 2001-9910	A	20010423
			GB 2001-11037	A	20010504
			WO 2001-GB5018	W	20011114

OTHER SOURCE(S): MARPAT 136:395983

IT 204066-82-0 204066-83-1 204066-84-2
204066-87-5 204066-89-7 204066-93-3
204066-95-5 204067-01-6 428864-38-4
428864-46-4 428864-51-1 428864-54-4
428864-57-7 428864-58-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin receptor antagonists, and combinations with other agents, for treatment of sexual dysfunction)

RN 204066-82-0 CAPLUS

CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-83-1 CAPLUS

CN 1H-Indole-3-propanamide, α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-84-2 CAPLUS

CN Benzoic acid, 4-[[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-87-5 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)



RN 204066-89-7 CAPLUS
CN Benzenepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-2-(trifluoromethyl)- (CA INDEX NAME)



RN 204066-93-3 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 204066-95-5 CAPLUS
CN 1H-Imidazole-5-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 428864-38-4 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(4-aminophenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 428864-46-4 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-benzodioxol-5-yl)-α-methyl- (CA INDEX NAME)



RN 428864-51-1 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-(2-phenylcyclohexyl)- (CA INDEX NAME)



RN 428864-54-4 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 428864-57-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 428864-58-8 CAPLUS
CN Benzenepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-2-nitro-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



L9 ANSWER 34 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:368981 CAPLUS
DOCUMENT NUMBER: 136:380137
TITLE: Bombesin receptor antagonists, and preparation thereof, for the treatment of sexual dysfunction
INVENTOR(S): Gonzalez, Maria Isabel; Pinnock, Robert Denham; Pritchard, Martyn Clive
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 72 pp., Cont.-in-part of U. S. Ser. No. 700,165.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020058606	A1	20020516	US 2001-759777	20010112
US 20020169101	A1	20021114	US 2001-999284	20011115
ZA 2003003249	A	20040623	ZA 2003-3249	20030425

PRIORITY APPLN. INFO.:

US 1999-133355P	P	19990510
WO 2000-GB1787	W	20000510
US 2000-700165	A2	20001109
US 2001-759777	A2	20010112
GB 2001-9910	A	20010423
GB 2001-11037	A	20010504

IT 204067-01-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bombesin receptor antagonists, preparation, and use for sexual dysfunction treatment, alone or with other agents)
RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 35 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:762968 CAPLUS
DOCUMENT NUMBER: 135:304105
TITLE: Preparation of nucleosides and isoindolinone derivatives as anti-inflammatory agents
INVENTOR(S): Japtap, Prakash; Southan, Garry; Salzman, Andrew; Szabo, Csaba; Ram, Siya
PATENT ASSIGNEE(S): Inotek Corporation, USA
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077075	A2	20011018	WO 2001-US11288	20010406
WO 2001077075	A3	20020328		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020095044	A1	20020718	US 2001-766053	20010119
US 6534651	B2	20030318		
US 20030149050	A1	20030807	US 2002-320780	20021216
US 6903079	B2	20050607		

PRIORITY APPLN. INFO.: US 2000-195622P P 20000406
US 2001-766053 A2 20010119

OTHER SOURCE(S): MARPAT 135:304105
IT 366454-25-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); IMF (Industrial manufacture); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP

(Preparation); USES (Uses)
(preparation of nucleosides and isoindolinone derivs. as anti-inflammatory agents)

RN 366454-25-3 CAPLUS

CN Adenosine, 5'-deoxy-5'-[[[[[(2,3-dihydro-1-oxo-1H-isoindol-4-yl)amino]carbonyl]amino]acetyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 36 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:380438 CAPLUS

DOCUMENT NUMBER: 135:24657

TITLE: Selective cellular targeting: multifunctional delivery vehicles

INVENTOR(S): Glazier, Arnold

PATENT ASSIGNEE(S): Drug Innovation & Design, Inc., USA

SOURCE: PCT Int. Appl., 981 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001036003	A2	20010525	WO 2000-US31262	20001114
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2391534	A1	20010525	CA 2000-2391534	20001114
AU 2001016075	A	20010530	AU 2001-16075	20001114
EP 1255567	A1	20021113	EP 2000-978631	20001114
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 20030138432	A1	20030724	US 2000-738625	20001215
PRIORITY APPLN. INFO.:			US 1999-165485P	P 19991115
			US 2000-239478P	P 20001011
			US 2000-241937P	P 20001020
			WO 2000-US31262	W 20001114
			US 2000-712465	B1 20001115

IT 341551-20-0P 341551-29-9P 341990-74-7P
RL: PNU (Preparation, unclassified); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(multifunctional delivery vehicles for selective cellular targeting of drugs)

RN 341551-20-0 CAPLUS

CN 1H-Indole-1-carboxylic acid, 3-[3-[[[1-[5-[[(16S)-13-[3-[bis(9H-fluoren-9-ylmethoxy)phosphinyl]propyl]-16-carboxy-20-(1,1-dioxidobenzo[b]thien-2-yl)-3,14,18-trioxo-7,10,19-trioxa-4,13,17-triazaeicos-1-yl]oxy]-2-pyridinyl]cyclohexyl]methyl]amino]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-3-oxopropyl]-, 1-(9H-fluoren-9-ylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



PAGE 2-B

PAGE 3-A



PAGE 3-B



RN 341551-29-9 CAPLUS
CN 1H-Indole-1-carboxylic acid, 3-[3-[[[1-[5-(2-carboxyethoxy)-2-pyridinyl]cyclohexyl]methyl]amino]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-3-oxopropyl]-, 1-(9H-fluoren-9-ylmethyl) ester (CA INDEX NAME)

PAGE 1-A





RN 341990-74-7 CAPLUS
CN L-Alaninamide, N12-[N-[3-[bis(9H-fluoren-9-ylmethoxy)phosphinyl]propyl]-N-[2-[2-[2-[[3-[[6-[1-[[[3-[1-[(9H-fluoren-9-ylmethoxy)carbonyl]-1H-indol-3-yl]-2-methyl-2-[[[(4-nitrophenyl)amino]carbonyl]amino]-1-oxopropyl]amino]methyl]cyclohexyl]-3-pyridinyl]oxy]-1-oxopropyl]amino]ethoxy]ethoxy]ethyl]-L-asparaginyl]-N23-[N-[2-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]amino]-1-methyl-2-oxoethyl]-4-methyl-1-oxopentyl]-3-(5,6,7,8-tetrahydro-1-naphthalenyl)-L-alanyl]-23-amino-3,6,9,15,18,21-hexaoxa-12-azatricosanoyl-D-seryl-N-[1-[[[(1-[1,1'-biphenyl]-4-yl-1-methylethoxy)carbonyl]amino]iminomethyl]-2-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-3-piperidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 3-A





PAGE 3-B





PAGE 4-A

PAGE 4-B

L9 ANSWER 37 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:61090 CAPLUS
DOCUMENT NUMBER: 134:247168
TITLE: Tyrosine 220 in the 5th transmembrane domain of the neuromedin B receptor is critical for the high selectivity of the peptoid antagonist PD168368
AUTHOR(S): Tokita, Kenji; Hocart, Simon J.; Katsuno, Tatsuro; Mantey, Samuel A.; Coy, David H.; Jensen, Robert T.

CORPORATE SOURCE: Digestive Diseases Branch, NIDDK, National Institutes of Health, Bethesda, MD, 20892-1804, USA
SOURCE: Journal of Biological Chemistry (2001), 276(1), 495-504
CODEN: JBCHA3; ISSN: 0021-9258
PUBLISHER: American Society for Biochemistry and Molecular Biology
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204066-82-0, PD168368
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(tyrosine 220 in the 5th transmembrane domain of neuromedin B receptor is critical for high selectivity of peptoid antagonist PD168368)
RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 38 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:854241 CAPLUS
DOCUMENT NUMBER: 134:172770
TITLE: Nonpeptide neuromedin B receptor antagonists inhibit the proliferation of C6 cells
AUTHOR(S): Moody, T. W.; Jensen, R. T.; Garcia, L.; Leyton, J.
CORPORATE SOURCE: Cell and Cancer Biology Department, Medicine Branch, National Cancer Institute, Bldg. KWC, Rm. 300, Rockville, MD, 20850, USA
SOURCE: European Journal of Pharmacology (2000), 409(2), 133-142
CODEN: EJPHAZ; ISSN: 0014-2999
PUBLISHER: Elsevier Science B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 185215-75-2, PD165929 204066-82-0, PD168368 204067-01-6, PD176252
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nonpeptide neuromedin B receptor antagonists inhibit proliferation of C6 cells)

RN 185215-75-2 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-82-0 CAPLUS

CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-01-6 CAPLUS

CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 39 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:819353 CAPLUS
DOCUMENT NUMBER: 132:64534
TITLE: Preparation of cyclic amino acid compounds for inhibiting β-amyloid peptide release and/or its synthesis
INVENTOR(S): Thompson, Richard C.; Wilkie, Stephen; Stack, Douglas R.; Vanmeter, Eldon E.; Shi, Qing; Britton, Thomas C.; Audia, James E.; Reel, Jon K.; Mabry, Thomas E.; Dressman, Bruce A.; Cwi, Cynthia L.; Henry, Steven S.; Mcdaniel, Stacey L.; Stucky, Russell D.; Porter, Warren J.
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Eli Lilly & Company; et al.
SOURCE: PCT Int. Appl., 714 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9967221	A1	19991229	WO 1999-US14193	19990622
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2325389	A1	19991229	CA 1999-2325389	19990622
AU 9947101	A	20000110	AU 1999-47101	19990622
EP 1089980	A1	20010411	EP 1999-930594	19990622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002518483	T	20020625	JP 2000-555875	19990622

US 20050192265 A1 20050901 US 2004-2922 20041203
PRIORITY APPLN. INFO.: US 1998-102507 A2 19980622
WO 1999-US14193 W 19990622
US 2003-392332 A3 20030320

OTHER SOURCE(S): MARPAT 132:64534
IT 253323-23-8P 253323-26-1P 253323-27-2P
253323-28-3P 253323-29-4P 253323-30-7P
253323-31-8P 253323-32-9P 253323-33-0P
253323-34-1P 253323-35-2P 253323-36-3P
253323-37-4P 253323-39-6P 253323-41-0P
253323-42-1P 253323-44-3P 253323-45-4P
253323-47-6P 253323-48-7P 253323-49-8P
253323-50-1P 253323-51-2P 253323-52-3P
253323-53-4P 253323-54-5P 253323-55-6P
253323-56-7P 253323-57-8P 253323-58-9P
253323-59-0P 253323-60-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of cyclic amino acid compds. for inhibiting β-amyloid peptide release)
RN 253323-23-8 CAPLUS
CN Propanamide, 2-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-26-1 CAPLUS
CN Propanamide, 2-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-27-2 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-28-3 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[(phenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-29-4 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-2-[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]amino]-,

ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-30-7 CAPLUS
CN Propanamide, 2-[[[(2-bromophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-31-8 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-methylphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-32-9 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-ethyl-6-methylphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-33-0 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-fluorophenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-34-1 CAPLUS
CN Propanamide, 2-[[[(2,4-difluorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-

dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-35-2 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-ethoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-36-3 CAPLUS
CN Propanamide, 2-[[[(3-acetylphenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-37-4 CAPLUS
CN Propanamide, 2-[[[(3-cyanophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-39-6 CAPLUS
CN Propanamide, 2-[[[(4-butylphenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-41-0 CAPLUS
CN Propanamide, 2-[[([1,1'-biphenyl]-4-ylamino)carbonyl]amino]-N-[(3S)-2,3-

dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-42-1 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-44-3 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[[2-(1-methylethyl)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-45-4 CAPLUS
CN Propanamide, 2-[[[(2,6-difluorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-47-6 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[[4-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-48-7 CAPLUS
CN Propanamide, 2-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-

dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-49-8 CAPLUS
CN Benzoic acid, 3-[[[[(1S)-2-[[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]amino]-1-methyl-2-oxoethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-50-1 CAPLUS
CN Propanamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-51-2 CAPLUS
CN Propanamide, 2-[[[(4-butoxyphenyl)amino]carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-52-3 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(4-phenoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-53-4 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-

benzodiazepin-3-yl]-2-[[(1-naphthalenylamino)carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-54-5 CAPLUS
CN Propanamide, 2-[[([1,1'-biphenyl]-2-ylamino)carbonyl]amino]-N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-55-6 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[[2-(methylthio)phenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-56-7 CAPLUS

CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2-ethylphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-57-8 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(3-methoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-58-9 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-59-0 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 253323-60-3 CAPLUS
CN Propanamide, N-[(3S)-2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepin-3-yl]-2-[[[[2-(1,1-dimethylethyl)-6-methylphenyl]amino]carbonyl]amino]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 40 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:547942 CAPLUS
DOCUMENT NUMBER: 131:281759
TITLE: Comparative pharmacology of the nonpeptide neuromedin B receptor antagonist PD 168368
AUTHOR(S): Ryan, Richard R.; Katsuno, Tatsuro; Mantey, Samuel A.; Pradhan, Tapas K.; Weber, H. Christian; Coy, David H.; Battey, James F.; Jensen, Robert T.
CORPORATE SOURCE: Digestive Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, USA
SOURCE: Journal of Pharmacology and Experimental Therapeutics (1999), 290(3), 1202-1211
CODEN: JPETAB; ISSN: 0022-3565
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 204066-82-0, PD 168368
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(comparative pharmacol. of nonpeptide neuromedin B receptor antagonist PD 168368 in human, mouse, rat and frog)
RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 41 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:660097 CAPLUS
DOCUMENT NUMBER: 130:20201
TITLE: PD 176252 - the first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist
AUTHOR(S): Ashwood, V.; Brownhill, V.; Higginbottom, M.; Horwell, D. C.; Hughes, J.; Lewthwaite, R. A.; McKnight, A. T.; Pinnock, R. D.; Pritchard, M. C.; Suman-Chauhan, N.;

Webb, C.; Williams, S. C.
CORPORATE SOURCE: Parke-Davis Neuroscience Research Centre, CAMBRIDGE, CB2 2QB, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(18), 2589-2594
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 185215-75-2, PD 165929 204066-81-9 204066-82-0
, PD 168368 204066-83-1 204067-01-6, PD 176252
216318-92-2 216319-01-6 216319-06-1
216319-16-3 216319-26-5 216319-32-3
216319-38-9 216319-44-7 216319-50-5
216319-55-0 216319-57-2 216319-58-3
216319-60-7 216319-62-9 216319-64-1
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(PD 176252 as first high affinity non-peptide gastrin-releasing peptide (BB2) receptor antagonist and structure-activity relations)
RN 185215-75-2 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-81-9 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-83-1 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216318-92-2 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[(phenylamino)carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-01-6 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-06-1 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-16-3 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[[4-(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-26-5 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(3-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-32-3 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(2-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-38-9 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[(1-phenylcyclohexyl)methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-44-7 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(4-hydroxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-50-5 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(4-nitrophenyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-55-0 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-[4-(dimethylamino)phenyl]cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-57-2 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-N-[[1-[4-(1-methylethyl)phenyl]cyclohexyl]methyl]-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-58-3 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(4-methoxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-60-7 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(4-ethoxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-62-9 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(2-methoxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 216319-64-1 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(3,4-dimethoxyphenyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 42 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:147326 CAPLUS
DOCUMENT NUMBER: 128:205147
ORIGINAL REFERENCE NO.: 128:40583a,40584a
TITLE: Preparation of non-peptide bombesin receptor antagonists
INVENTOR(S): Horwell, David Christopher; Pritchard, Martyn Clive
PATENT ASSIGNEE(S): Warner-Lambert Company, USA; Horwell, David Christopher; Pritchard, Martyn Clive
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9807718	A1	19980226	WO 1997-US13871	19970806
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
BR 9711342	A	19990817	BR 1997-11342	19970222
CA 2255966	A1	19980226	CA 1997-2255966	19970806
AU 9741466	A	19980306	AU 1997-41466	19970806
AU 733226	B2	20010510		
EP 920424	A1	19990609	EP 1997-939359	19970806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
HU 9903968	A2	20000228	HU 1999-3968	19970806
HU 9903968	A3	20011128		
NZ 333038	A	20001027	NZ 1997-333038	19970806
JP 2001500850	T	20010123	JP 1998-510779	19970806
AT 311383	T	20051215	AT 1997-939359	19970806

ES 2253782	T3	20060601	ES 1997-939359		19970806
ZA 9707526	A	19980219	ZA 1997-7526		19970821
US 6194437	B1	20010227	US 1999-230933		19990203
NO 9900788	A	19990219	NO 1999-788		19990219
NO 312669	B1	20020617			
PRIORITY APPLN. INFO.:			US 1996-24323P	P	19960822
			WO 1997-US13871	W	19970806

OTHER SOURCE(S): MARPAT 128:205147

IT 204066-87-5P 204067-04-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of non-peptide bombesin receptor antagonists)

RN 204066-87-5 CAPLUS

CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, 1-oxide (CA INDEX NAME)



RN 204067-04-9 CAPLUS

CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-[1-(triphenylmethyl)-1H-imidazol-4-yl]cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 142627-75-6P 185215-75-2P 204066-74-0P
204066-81-9P 204066-82-0P 204066-83-1P
204066-84-2P 204066-89-7P 204066-91-1P
204066-93-3P 204066-95-5P 204066-99-9P

204067-01-6P 204067-02-7P 204067-05-0P
204067-06-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of non-peptide bombesin receptor antagonists)

RN 142627-75-6 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 185215-75-2 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-74-0 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[(1S,2S)-2-phenylcyclohexyl]-, (αR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 204066-81-9 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-82-0 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-83-1 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-α-[[[[4-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-84-2 CAPLUS
CN Benzoic acid, 4-[[[[(1S)-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-[[[1-(2-pyridinyl)cyclohexyl]methyl]amino]ethyl]amino]carbonyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 204066-89-7 CAPLUS
CN Benzenepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbony
l]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-2-
(trifluoromethyl)- (CA INDEX NAME)



RN 204066-91-1 CAPLUS
CN Benzenepropanamide, α-methyl-2-nitro-α-[[[(4-
nitrophenyl)amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-
(CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 204066-93-3 CAPLUS
CN 2-Pyridinepropanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 204066-95-5 CAPLUS
CN 1H-Imidazole-5-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]- (CA INDEX NAME)



RN 204066-99-9 CAPLUS
CN 1H-Indole-3-propanamide, α-methyl-N-[[1-(2-methyl-4-thiazolyl)cyclohexyl]methyl]-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-01-6 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-02-7 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-[4-[(dimethylamino)methyl]phenyl]cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-05-0 CAPLUS
CN 1H-Indole-3-propanamide, N-[[1-(1H-imidazol-5-yl)cyclohexyl]methyl]-α-methyl-α-[[[(4-nitrophenyl)amino]carbonyl]amino]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 204067-06-1 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[(4-cyanophenyl)amino]carbonyl]amino]-N-[[1-(5-methoxy-2-pyridinyl)cyclohexyl]methyl]-α-methyl-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



IT 204067-26-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of non-peptide bombesin receptor antagonists)
RN 204067-26-5 CAPLUS
CN 1H-Imidazole-4-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-1-(triphenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 43 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:615095 CAPLUS
DOCUMENT NUMBER: 127:288296
ORIGINAL REFERENCE NO.: 127:56165a,56168a
TITLE: Construction of chimeric human bombesin receptors to identify neuromedin B and gastrin-releasing peptide receptor binding sites
AUTHOR(S): Maughfling, Edward J. R.; Boden, Philip; Hall, Matthew D.
CORPORATE SOURCE: Parke-Davis Neuroscience Research Centre, Cambridge,

CB2 2QB, UK
SOURCE: Biochemical Society Transactions (1997), 25(3), 455S
CODEN: BCSTB5; ISSN: 0300-5127
PUBLISHER: Portland Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 185215-75-2, PD 165929
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(construction of chimeric human bombesin receptors to identify neuromedin B and gastrin-releasing peptide receptor binding sites)
RN 185215-75-2 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 44 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:70350 CAPLUS
DOCUMENT NUMBER: 126:199453
ORIGINAL REFERENCE NO.: 126:38559a,38562a
TITLE: Preparation of adamantyl indolylalkylcarbamates and analogs as cholecystokinin antagonists
INVENTOR(S): Horwell, David C.; Roberts, Edward; Holmes, Ann; Padia, Janak K.; Roark, William H.; Roth, Bruce D.; Trivedi, Bharat K.; Kleinschroth, Jurgen; Rees, David C.; Richardson, Reginald S.
PATENT ASSIGNEE(S): Warner-Lambert Company, USA
SOURCE: U.S., 77 pp., Cont.-in-part of U.S. Ser. No. 839, 647, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5593967	A	19970114	US 1993-41647	19930401
ZA 9106922	A	19930301	ZA 1991-6922	19910830

US 5846942 A 19981208 US 1996-709316 19960909
PRIORITY APPLN. INFO.: US 1990-576628 B2 19900831
US 1991-726655 B2 19910712
US 1992-839647 B2 19920221
US 1993-41647 A3 19930401

OTHER SOURCE(S): MARPAT 126:199453

IT 142627-75-6P 142627-76-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of adamantyl indolylalkylcarbamates and analogs as cholecystokinin antagonists)

RN 142627-75-6 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142627-76-7 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 45 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:741361 CAPLUS
DOCUMENT NUMBER: 126:54301
ORIGINAL REFERENCE NO.: 126:10551a,10554a
TITLE: PD 165929 - the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist
AUTHOR(S): Eden, J. M.; Hall, M. D.; Higginbottom, M.; Horwell, D. C.; Howson, W.; Hughes, J.; Jordon, R. E.; Lewthwaite, R. A.; Martin, K.; McKnight, A. T.
CORPORATE SOURCE: Park-Davis Neurosci. Res. Cent., Cambridge, CB2 2QB, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (1996), 6(21), 2617-2622
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
IT 185215-75-2, PD 165929
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(PD 165929 - the first high affinity non-peptide neuromedin-B (NMB) receptor selective antagonist)
RN 185215-75-2 CAPLUS
CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-α-methyl-N-[[1-(2-pyridinyl)cyclohexyl]methyl]-, (αS)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 46 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:255359 CAPLUS
DOCUMENT NUMBER: 118:255359
ORIGINAL REFERENCE NO.: 118:44401a,44404a
TITLE: Cyclopropenone peptide derivatives
INVENTOR(S): Ando, Ryoichi; Morinaka, Yasuhiro; Takahashi, Chizuko; Tamao, Yoshikuni; Tobe, Akirhiro
PATENT ASSIGNEE(S): Mitsubishi Kasei Corp., Japan
SOURCE: Eur. Pat. Appl., 151 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 520427	A1	19921230	EP 1992-110674	19920625
EP 520427	B1	19941214		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE				
JP 05230004	A	19930907	JP 1992-146024	19920605
JP 3228347	B2	20011112		
CA 2072416	A1	19921226	CA 1992-2072416	19920625
CA 2072416	C	20060321		
US 5328909	A	19940712	US 1992-905544	19920625
ES 2068646	T3	19950416	ES 1992-110674	19920625
US 5416117	A	19950516	US 1994-202555	19940228

PRIORITY APPLN. INFO.:
JP 1991-153500 A 19910625
JP 1991-277904 A 19911024
JP 1991-341497 A 19911224
JP 1992-146024 A 19920605
US 1992-905544 A3 19920625

OTHER SOURCE(S): MARPAT 118:255359
IT 147660-52-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and thiol protease inhibitory activity of)
RN 147660-52-4 CAPLUS
CN Pentanamide, N-[1-[hydroxy(3-oxo-2-phenyl-1-cyclopropen-1-yl)methyl]-2-methylpropyl]-4-methyl-2-[[(phenylamino)carbonyl]amino]-, [2S-[1[R*(R*)],2R*]]- (9CI) (CA INDEX NAME)



L9 ANSWER 47 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:484251 CAPLUS
DOCUMENT NUMBER: 117:84251
ORIGINAL REFERENCE NO.: 117:14559a,14562a
TITLE: Cholecystokinin antagonists, their preparation and therapeutic use
INVENTOR(S): Horwell, David Christopher; Kleinschroth, Juergen; Rees, David Charles; Richardson, Reginald Stewart; Roark, William Howard; Roberts, Edward; Roth, Bruce David; Trivedi, Bharat Kalidas; Holmes, Ann; Padia, Janak Khimchand
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 211 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9204045	A1	19920319	WO 1991-US6180	19910829
W: AU, CA, FI, JP, KR, NO				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
AU 9187492	A	19920330	AU 1991-87492	19910829
AU 651390	B2	19940721		
EP 547178	A1	19930623	EP 1991-918880	19910829
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06502627	T	19940324	JP 1991-517185	19910829
ZA 9106922	A	19930301	ZA 1991-6922	19910830
NO 9300709	A	19930415	NO 1993-709	19930226
NO 312298	B1	20020422		

PRIORITY APPLN. INFO.: US 1990-576628 A 19900831
US 1991-726655 A 19910712
WO 1991-US6180 A 19910829

OTHER SOURCE(S): MARPAT 117:84251

IT 142627-75-6P 142627-76-7P
RL: RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reaction of, for cholecystokinin antagonist)

RN 142627-75-6 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 142627-76-7 CAPLUS

CN 1H-Indole-3-propanamide, α-[[[[2,6-bis(1-methylethyl)phenyl]amino]carbonyl]amino]-N-(2,2-dimethyl-4-phenyl-1,3-dioxan-5-yl)-α-methyl-, [4S-[4α,5α(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 48 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:43487 CAPLUS
DOCUMENT NUMBER: 114:43487
ORIGINAL REFERENCE NO.: 114:7585a,7588a
TITLE: Preparation of nikkomycin derivatives as antimycotics
INVENTOR(S): Schaller, Klaus; Moeschler, Heinrich Ferdinand; Plempel, Manfred; Hector, Richard
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 367954	A1	19900516	EP 1989-117435		19890921
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, NL, SE					
US 5019560	A	19910528	US 1988-252613		19881003
JP 02174791	A	19900706	JP 1989-257169		19891003
US 5149795	A	19920922	US 1991-674255		19910325
PRIORITY APPLN. INFO.:			US 1988-252613	A	19881003

OTHER SOURCE(S): MARPAT 114:43487
IT 131396-40-2P 131396-41-3P 131396-42-4P
131396-43-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as antimycotic)
RN 131396-40-2 CAPLUS
CN β-D-Allofuranuronic acid, 1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-5-[[4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxo-2-[[(phenylamino)carbonyl]amino]butyl]amino]-, [2S-(2R*,3R*,4R*)]- (9CI) (CA INDEX NAME)



RN 131396-41-3 CAPLUS
CN β-D-Allofuranuronic acid, 5-[[2-[[[(3-chlorophenyl)amino]carbonyl]amino]-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxobutyl]amino]-1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-, [2S-(2R*,3R*,4R*)]- (9CI) (CA INDEX NAME)



RN 131396-42-4 CAPLUS
CN β-D-Allofuranuronic acid, 1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-5-[[4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-methyl-1-oxo-2-[[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]butyl]amino]-, [2S-(2R*,3R*,4R*)]- (9CI) (CA INDEX NAME)



RN 131396-43-5 CAPLUS
CN β-D-Allofuranuronic acid, 5-[[2-[[[(3-chloro-4-methylphenyl)amino]carbonyl]amino]-4-hydroxy-4-(5-hydroxy-2-pyridinyl)-3-

methyl-1-oxobutyl]amino]-1,5-dideoxy-1-(4-formyl-2,3-dihydro-2-oxo-1H-imidazol-1-yl)-, [2S-(2R*,3R*,4R*)]- (9CI) (CA INDEX NAME)



L9 ANSWER 49 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1984:193520 CAPLUS
DOCUMENT NUMBER: 100:193520
ORIGINAL REFERENCE NO.: 100:29427a,29430a
TITLE: Synthesis of 3-aryl-4-methyl-7-substituted aminocoumarins as optical brighteners
AUTHOR(S): Desai, K. R.; Patel, K. C.
CORPORATE SOURCE: Dep. Chem., South Gujarat Univ., Surat, 395 007, India
SOURCE: Journal of the Institution of Chemists (India) (1983), 55(5), 199-200
CODEN: JOICA7; ISSN: 0020-3254
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 89206-56-4P 89206-57-5P 89206-58-6P
89206-59-7P 89206-60-0P 89206-61-1P
89206-62-2P 89206-63-3P 89206-64-4P
89206-65-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, for use as fluorescent brightener)
RN 89206-56-4 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[(phenylamino)carbonyl]amino]- (CA INDEX NAME)



RN 89206-57-5 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[[(2-methylphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 89206-58-6 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[[(3-methylphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 89206-59-7 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[[(4-methylphenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 89206-60-0 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[[(2-nitrophenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 89206-61-1 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[[(3-nitrophenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 89206-62-2 CAPLUS
CN Acetamide, N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)-2-[[[(4-nitrophenyl)amino]carbonyl]amino]- (CA INDEX NAME)



RN 89206-63-3 CAPLUS
CN Acetamide, 2-[[[(2-chlorophenyl)amino]carbonyl]amino]-N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)- (CA INDEX NAME)



RN 89206-64-4 CAPLUS
CN Acetamide, 2-[[[(3-chlorophenyl)amino]carbonyl]amino]-N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)- (CA INDEX NAME)



RN 89206-65-5 CAPLUS
CN Acetamide, 2-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-(4-methyl-2-oxo-3-phenyl-2H-1-benzopyran-7-yl)- (CA INDEX NAME)



L9 ANSWER 50 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:439467 CAPLUS
DOCUMENT NUMBER: 91:39467
ORIGINAL REFERENCE NO.: 91:6441a,6444a
TITLE: Antibacterial 3-(5-tetrazolyl)penam compounds
INVENTOR(S): Barth, Wayne E.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 81 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4143039	A	19790306	US 1977-786817	19770412
BE 821163	A1	19750417	BE 1974-1006234	19741017
ZA 7406519	A	19751126	ZA 1974-6519	19741017
AT 7408363	A	19761215	AT 1974-8363	19741017
AT 338418	B	19770825		
AT 7508843	A	19771015	AT 1975-8843	19751120
CS 193547	B2	19791031	CS 1977-2901	19770503
DK 7702690	A	19770617	DK 1977-2690	19770617
DK 152502	B	19880307		
DK 152502	C	19880725		
DK 7804563	A	19781013	DK 1978-4563	19781013
DK 7804564	A	19781013	DK 1978-4564	19781013
US 4179511	A	19791218	US 1978-957197	19781101
FI 8002003	A	19800623	FI 1980-2003	19800623
FI 60398	B	19810930		
FI 60398	C	19820111		

PRIORITY APPLN. INFO.:

US 1973-407097	A2	19731017
US 1974-450435	A2	19740312
US 1974-491510	A2	19740724
US 1975-561147	A2	19750324
CS 1974-7099	A3	19741016
DK 1974-5419	A	19741016
DK 1974-5421	A	19741016
FI 1974-3024	A	19741016
AT 1974-8363	A	19741017
US 1977-786817	A3	19770412

OTHER SOURCE(S): MARPAT 91:39467
IT 69223-27-4P 69223-28-5P 69223-30-9P
69223-31-0P 69223-33-2P 69223-34-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 69223-27-4 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-

azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-
[[(phenylamino)carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-28-5 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-
azabicyclo[3.2.0]hept-6-yl]-α-[[[(4-methoxyphenyl)amino]carbonyl]ami
no]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-30-9 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-
azabicyclo[3.2.0]hept-6-yl]-α-[[[(4-methylphenyl)amino]carbonyl]amin
o]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-31-0 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[(phenylamino)carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-33-2 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-34-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3,3-

dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 70379-36-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 70379-36-1 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-[[(phenylamino)carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]-, compd. with N,N-diethylethanamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 69223-27-4
CMF C23 H24 N8 O4 S

Absolute stereochemistry.



CM 2

CRN 121-44-8
CMF C6 H15 N



L9 ANSWER 51 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1979:152170 CAPLUS
DOCUMENT NUMBER: 90:152170
ORIGINAL REFERENCE NO.: 90:24197a,24200a
TITLE: Antibacterial 3-(5-tetrazolyl)penam compounds
INVENTOR(S): Barth, Wayne E.
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: U.S., 81 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4115385	A	19780919	US 1977-786952	19770412
BE 821163	A1	19750417	BE 1974-1006234	19741017
ZA 7406519	A	19751126	ZA 1974-6519	19741017
AT 7408363	A	19761215	AT 1974-8363	19741017
AT 338418	B	19770825		
AT 7508843	A	19771015	AT 1975-8843	19751120
CS 193547	B2	19791031	CS 1977-2901	19770503
DK 7702690	A	19770617	DK 1977-2690	19770617
DK 152502	B	19880307		
DK 152502	C	19880725		
DK 7804563	A	19781013	DK 1978-4563	19781013
DK 7804564	A	19781013	DK 1978-4564	19781013
FI 8002003	A	19800623	FI 1980-2003	19800623
FI 60398	B	19810930		
FI 60398	C	19820111		

PRIORITY APPLN. INFO.:

US 1973-407097	A2	19731017
US 1974-450435	A2	19740312
US 1974-491510	A2	19740724
US 1975-561147	A2	19750324
CS 1974-7099	A3	19741016
DK 1974-5419	A	19741016
DK 1974-5421	A	19741016
FI 1974-3024	A	19741016
AT 1974-8363	A	19741017

IT 69223-27-4P 69223-28-5P 69223-29-6P
69223-30-9P 69223-31-0P 69223-33-2P
69223-34-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and bactericidal activity of)
RN 69223-27-4 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-[[(phenylamino)carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-28-5 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-29-6 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-30-9 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[[(4-methylphenyl)amino]carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-31-0 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[(phenylamino)carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-33-2 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 69223-34-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-, [2S-[2α,5α,6β(S*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L9 ANSWER 52 OF 52 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1975:514393 CAPLUS
DOCUMENT NUMBER: 83:114393
ORIGINAL REFERENCE NO.: 83:17971a,17974a
TITLE: Antibiotic penam derivatives
INVENTOR(S): Barth, Wayne E.
PATENT ASSIGNEE(S): Pfizer, Inc., USA
SOURCE: Ger. Offen., 175 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2449863	A1	19750430	DE 1974-2449863	19741017
DE 2449863	B2	19790705		
DE 2449863	C3	19800228		
SE 7412234	A	19750418	SE 1974-12234	19740927
SE 425788	B	19821108		
SE 425788	C	19830217		
CA 1059992	A1	19790807	CA 1974-211057	19741009
IL 45833	A	19780731	IL 1974-45833	19741011
RO 70536	A1	19810530	RO 1974-90550	19741015
FI 7403024	A	19750418	FI 1974-3024	19741016
FI 59411	B	19810430		
FI 59411	C	19810810		
FI 7403025	A	19750418	FI 1974-3025	19741016
NO 7403738	A	19750418	NO 1974-3738	19741016
NO 147915	B	19830328		
NO 147915	C	19830706		
NL 7413589	A	19750421	NL 1974-13589	19741016
NL 178508	B	19851101		
NL 178508	C	19860401		
DK 7405419	A	19750616	DK 1974-5419	19741016
DK 150515	B	19870316		

DK 150515	C	19870928			
DD 114082	A5	19750712	DD 1974-181738		19741016
ES 431064	A1	19770216	ES 1974-431064		19741016
CH 603664	A5	19780831	CH 1974-13891		19741016
CH 605979	A5	19781013	CH 1977-3835		19741016
CS 193505	B2	19791031	CS 1974-7099		19741016
HU 174960	B	19800428	HU 1974-PI434		19741016
BE 821163	A1	19750417	BE 1974-1006234		19741017
FR 2248044	A1	19750516	FR 1974-35014		19741017
JP 50064295	A	19750531	JP 1974-118742		19741017
JP 57040839	B	19820830			
ZA 7406519	A	19751126	ZA 1974-6519		19741017
AU 7474424	A	19760429	AU 1974-74424		19741017
AT 7408363	A	19761215	AT 1974-8363		19741017
AT 338418	B	19770825			
DE 2462675	B1	19790517	DE 1974-2462675		19741017
DE 2462675	C2	19800103			
IN 143272	A1	19771029	IN 1974-CA2348		19741028
AT 7508843	A	19771015	AT 1975-8843		19751120
CS 193547	B2	19791031	CS 1977-2901		19770503
DK 7702690	A	19770617	DK 1977-2690		19770617
DK 152502	B	19880307			
DK 152502	C	19880725			
SE 7708594	A	19770726	SE 1977-8594		19770726
DK 7804563	A	19781013	DK 1978-4563		19781013
DK 7804564	A	19781013	DK 1978-4564		19781013
NO 7803827	A	19750418	NO 1978-3827		19781114
NO 148526	B	19830718			
NO 148526	C	19831026			
FI 8002003	A	19800623	FI 1980-2003		19800623
FI 60398	B	19810930			
FI 60398	C	19820111			
JP 57145882	A	19820909	JP 1982-7361		19820120
JP 58022480	B	19830509			

PRIORITY APPLN. INFO.:

US 1973-407097	A	19731017
US 1974-450435	A	19740312
CS 1974-7099	A3	19741016
DK 1974-5419	A	19741016
DK 1974-5421	A	19741016
FI 1974-3024	A	19741016
AT 1974-8363	A	19741017

IT 56852-12-1P 56853-10-2P 56853-11-3P
56853-12-4P 56853-13-5P 56853-15-7P
56854-26-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 56852-12-1 CAPLUS

CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-[[(phenylamino)carbonyl]amino]-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56853-10-2 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56853-11-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56853-12-4 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[[(4-methylphenyl)amino]carbonyl]amin

o]-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56853-13-5 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-α-[[(phenylamino)carbonyl]amino]-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56853-15-7 CAPLUS
CN Benzeneacetamide, N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-α-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 56854-26-3 CAPLUS
CN Benzeneacetamide, α-[[[(4-chlorophenyl)amino]carbonyl]amino]-N-[3,3-dimethyl-7-oxo-2-(1H-tetrazol-5-yl)-4-thia-1-azabicyclo[3.2.0]hept-6-yl]-4-hydroxy-, [2S-(2α,5α,6β)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=>